EP0730605A1 - Substituted di- and tripeptide inhibitors of protein:farnesyl transferase - Google Patents

Substituted di- and tripeptide inhibitors of protein:farnesyl transferase

Info

Publication number
EP0730605A1
EP0730605A1 EP94930725A EP94930725A EP0730605A1 EP 0730605 A1 EP0730605 A1 EP 0730605A1 EP 94930725 A EP94930725 A EP 94930725A EP 94930725 A EP94930725 A EP 94930725A EP 0730605 A1 EP0730605 A1 EP 0730605A1
Authority
EP
European Patent Office
Prior art keywords
obn
tyr
cbz
ser
conh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94930725A
Other languages
German (de)
French (fr)
Inventor
Gary Louis Bolton
Mark Wallace Creswell
John Cooke Hodges
Michael William Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of EP0730605A1 publication Critical patent/EP0730605A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention pertains to a number of compounds which can be used in the medicinal field to treat, prophylactically or otherwise, uncontrolled or abnormal proliferation of human tissues. More specifically, the present invention pertains to a number of compounds which act to inhibit the farnesyl transferase enzyme that has been determined to activate ras proteins which in turn activate cellular division and are implicated in cancer and restenosis.
  • Ras protein (or p21) has been examined extensively because mutant forms are found in 20% of most types of human cancer and greater than 50% of colon and pancreatic carcinomas (Gibbs J.B., Cell, 65:1 (1991), Cartwright T. , et al. , Chimica Ocr ⁇ i. 10 . :26 (1992)) .
  • These mutant ras proteins are deficient in the capability for feedback regulation that is present in native ras and this deficiency is associated with their oncogenic action since the ability to stimulate normal cell division can not be controlled by the normal endogenous regulatory cofactors.
  • the recent discovery that the transforming activity of mutant ras is critically dependent on post-translational modifications (Gibbs J., et al.
  • blockade of ras dependant processes has the potential to reduce or eliminate the inappropriate tissue proliferation associated with restenosis, particularly in those instances where normal ras expression and/or function is exaggerated by growth stimulatory factors.
  • Ras functioning is dependent upon the modification of the proteins in order to associate with the inner face of plasma membranes.
  • ras proteins lack conventional transmembrane or hydrophobic sequences and are initially synthesized in a cytosol soluble form.
  • Ras protein membrane association is triggered by a series of posttranslational processing steps that are signaled by a carboxyl terminal amino acid consensus sequence that is recognized by protein:farnesyl transferase. This consensus sequence consists of a cysteine residue located four amino acids from the carboxyl terminus, followed by two lipophilic amino acids and the C-terminal residue.
  • the sulfhydryl group of the cysteine residue is alkylated by farnesyl pyrophosphate in a reaction that is catalyzed by protein:farnesyl transferase.
  • the C-terminal three amino acids are cleaved by an endoprotease and the newly exposed alpha-carboxyl group of the prenylated cysteine is methylated by a methyl transferase.
  • the enzymatic processing of ras proteins that begins with farnesylation enables the protein to associate with the cell membrane. Mutational analysis of oncogenic ras proteins indicate that these posttranslational modifications are essential for transforming activity.
  • PFTs protein:farnesyl transferases
  • farnesyl:protein transferases protein:farnesyl transferases
  • the enzyme was charac ⁇ terized as a heterodimer composed of one alpha-subunit (49 kDa) and one beta-subunit (46 kDa) , both of which are required for catalytic activity.
  • PCT Application O91/16340 discloses cysteine containing tetrapeptide inhibitors of PFT of the formula CAAX.
  • European Patent Application 0461869 discloses cysteine containing tetrapeptide inhibitors of PFT of the formula Cys-Aaa 1 -Aaa 2 -Xaa.
  • European Patent Application 0520823 discloses cysteine containing tetrapeptide inhibitors of PFT of the formula Cys-Xaa 1 -dXaa 2 -Xaa 3 .
  • European Patent Application 0523873 discloses cysteine containing tetrapeptide inhibitors of PFT of the formula Cys-Xaa 1 -Xaa 2 -Xaa 3 . 2612
  • European Patent Application 0528486 discloses cysteine containing tetrapeptide amides inhibitors of PFT of the formula Cys-Xaa 1 -Xaa 2 -Xaa 3 -NRR 1 .
  • US 4,022,759 discloses tripeptide antagonists of luteinizing hormone releasing factor of the formula A-R- ⁇ Tyr(benzyl) -Ser(benzyl) -R 2 , wherein one of the definitions of R- j ⁇ is His (benzyl) .
  • the present invention is a substituted di- or tripeptide compound of Formula I:
  • n 1 or 2;
  • A COR 3 , C0 2 R 3 , CONHR 3 , CSR 3 , C(S)OR 3 , C(S)NHR 3 , CF 3 S0 2 , aryl-S0 2 , or alkyl-S0 2 , wherein R 3 is alkyl, (CH 2 ) m -cycloalkyl, (CH 2 ) m -aryl,
  • R 1 H, CO-aryl, (CH 2 ) m -aryl, 0(CH 2 ) m -cycloalkyl,
  • X one to four substituents, including H, alkyl, CF 3 , F, Cl, Br, I, HO, MeO, N0 2 , NH 2 , N(Me) 2 , 0P0 3 H 2 , or
  • R 2 NR(CH 2 ) n C0 2 R 3 , NR(CH 2 ) n CONHR 3 , NR(CH 2 ) n R 3 , NR(CH 2 ) n+1 OR 4 , NR(CH 2 ) n+1 SR 4 , NRCH(COR 5 ) (CH 2 ) n -heteroaryl, NRCH(C0R 5 ) (CH 2 ) n OR 3 ,
  • the present invention is also directed to the use of a compound of Formula I, or a pharmaceutically acceptable salt therefrom, to inhibit the activity of a protein:farnesyl transferase enzyme as a method for treating tissue proliferative diseases.
  • a further embodiment of the present invention is the use of a pharmaceutical composition including an effective amount of a compound of Formula I as a method for the treatment of cancer. 12612
  • a still further embodiment of the present invention is the use of a pharmaceutical composition including an effective amount of a compound of Formula I as a method for the treatment of restenosis.
  • a still further embodiment of the present invention is a pharmaceutical composition for administering an effective amount of a compound of Formula I in unit dosage form in the treatment methods mentioned above.
  • a final embodiment of the present invention pertains to methods for the preparation of compounds of Formula I by solid phase synthesis, solution phase synthesis, and simultaneous multiple syntheses using a multiple simultaneous synthesis apparatus.
  • alkyl means a straight or branched hydrocarbon radical having from 1 to 6 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and the like.
  • cycloalkyl means a saturated hydrocarbon ring which contains from 3 to 10 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, and the like, unsubstituted or substituted by an alkyl or aryl group.
  • heteroaryl means a heteroaromatic ring which is a 2- or 3-thienyl, 2- or 3-furanyl, 2- or 3-pyrrolyl, 2-, 3- or 4-pyridyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl group, unsubstituted or with 1 or 2 substituents from the group of substituents described above for aryl.
  • the amino acid or abbreviation is preceded by the appropriate configuration D(R) or DL(RS) . 12612
  • Gly-C0 2 Bn is Glycine, benzyl ester
  • Ser(OBn) -C0 2 Me is O-Benzyl-serine, methyl ester.
  • Gly-CONHBn is Glycine, N-benzyl amide
  • Ser(OBn) -CONHEt is O-Benzyl-serine, N-ethyl amide
  • Tyr(OBn) -CONHCH 2 CH 2 OBn is O-Benzyl- tyrosine, N- (2- (phenylmethoxy)ethyl) amide.
  • optical activity of the amino acid is other than L(S)
  • the amino acid or abbreviation is preceded by the appropriate configuration D(R) or DL(RS) . 12612
  • optical activity of the amino acid is other than L(S)
  • the amino acid or abbreviation is preceded by the appropriate configuration D(R) or DL(RS) . -12-
  • Preferred compounds of Formula I consist of compounds of Formula II below:
  • R independently H or Me
  • Y independently H or Me
  • Z independently H or Me
  • R 1 (CH 2 ) m -aryl, 0(CH 2 ) m -aryl, OP0 3 H 2 , or CH 2 P0 3 H 2 , wherein m is as defined above;
  • R ⁇ NR(CH 2 ) 2 0R 4 , NR(CH 2 ) 2 SR 4 , NRCH(COR 5 ) CH 2 OR 3 ,
  • A is CONHR 3
  • R 2 is (CH 2 ) 2 0R 4
  • at least one of Y and Z is Me.
  • the most preferred compounds of Formula I include the following: Cbz-His-Tyr(OBn) -Ser(OBn) -C0 2 Me;
  • the compounds of Formula I may be prepared by solid phase peptide synthesis on a peptide synthesizer, for example, an Applied Biosystems 431A peptide synthesizer using activated esters or anhydrides of Boc or Fmoc protected amino acids, acid chlorides, isocyanates, isothiocyanates, etc., on PAM, MBHA, or NH 2 -Rink resins with solution phase modifications to the carboxyl terminus as appropriate.
  • Methodology for the solid phase synthesis of peptides is widely known to those skilled in the art thereof (see, for example: J.M. Stewart and J.D. Young in Solid Phase Peptide Synthesis: Pierce Chemical Co.; Rockford, IL (1984); Fields G.B. and Noble R.L.
  • the compounds of Formula I may also be prepared by conventional solution peptide synthesis, substituting amines, acid chlorides, isocyanates, etc, for amino acid derivatives where appropriate. Methods for solution phase synthesis of peptides are widely known to those skilled in the art (see, for example, M. Bodanszky, Principles of Peptide Synthesis. Springer-Verlag (1984)) .
  • the compounds of Formula I may be prepared by simultaneous multiple solid phase syntheses using an apparatus described by S. H. DeWitt, et al. , Proc. Natl. Acad. Sci. USA. 9 . 0:6909 (1993), and referred to by the trademark, DiversomerTM, both trademark and apparatus being owned in whole by the Warner-Lambert Company.
  • the multiple solid phase synthesis apparatus is currently the subject of now abandoned US Serial 07/958,383 filed October 8, 1992 and pending continuation-in-part US Serial 08/012,557 filed February 2, 1993.
  • Fmoc-D-His-Tyr(OBn) - C0 2 -CH 2 CH 2 Si (CH 3 ) 3 is linked to 2-Cl-Tr resin using a sterically hindered amine such as DIEA as an HC1 scavenger, the Fmoc protecting group is removed with piperidine, the resulting free amino terminus is acylated with a series of isocyanates, isothiocyanates, activated esters, acid chlorides and the like, the TMS-ethyl ester is cleaved with TBAF, the resulting 12612
  • - 19 - free carboxy terminus is activated with a carbodiimide reagent such as EDAC, DCC, or DIC, the activated carboxyl group is reacted with alcohols such as HOBT, NHOS, or pentachlorophenol to give an activated ester, the activated ester is reacted with a series of amines and the resulting array of compounds of Formula I is cleaved from the resin by with hot HOAc or by treatment with TFA at room temperature.
  • a carbodiimide reagent such as EDAC, DCC, or DIC
  • alcohols such as HOBT, NHOS, or pentachlorophenol
  • the activated ester is reacted with a series of amines and the resulting array of compounds of Formula I is cleaved from the resin by with hot HOAc or by treatment with TFA at room temperature.
  • RP-HPLC reverse phase-high pressure liquid chromatography
  • TLC capillary electrophoresis
  • NMR proton nuclear magnetic resonance spectrometry
  • amino acid analysis amino acid analysis
  • FAB-MS fast atom bombardment mass spectrometry
  • ES-MS electrospray mass spectrometry
  • the compounds of Formula I are capable of further forming both pharmaceutically acceptable acid addition and/or base salts. All of these forms are within the scope of the present invention.
  • Pharmaceutically acceptable acid addition salts of the compounds of Formula I include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc.
  • Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like.
  • salts of amino acids such as arginate and the like and gluconate, galacturonate, n-methyl glucamine (see, for example, Berge S.M., et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science. £6:1-19 (1977)).
  • the acid addition salts of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner.
  • a compound of Formula I can be converted to an acidic salt by treating with an aqueous solution of the desired acid, such that the resulting pH is less than 4.
  • the solution can be passed through a C18 cartridge to absorb the compound, washed with copious amounts of water, the compound eluted with a polar organic solvent such as, for example, methanol, acetonitrile, and the like, and isolated by concentrating under reduced pressure followed by lyophilization.
  • the free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner or as above.
  • the free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.
  • Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines.
  • metals used as cations are sodium, potassium, magnesium, calcium, and the like.
  • suitable amines are N,N' -dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge S.M., et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science. 6£: 1 - 19 (1977)).
  • the base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner.
  • a compound of Formula I can be converted to a base salt by treating with an aqueous solution of the desired base, such that the resulting pH is greater than 9.
  • the solution can be passed through a C18 cartridge to absorb the compound, washed with copious amounts of water, the compound eluted with a polar organic solvent such as, for example, methanol, acetonitrile and the 2612
  • the free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner or as above.
  • the free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention.
  • Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R(D) or S(L) configuration. The present invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof.
  • the PFT inhibitory activity of compounds of Formula I was assayed in 30 mM potassium phosphate buffer, pH 7.4, containing 7 mM DTT, l. ' 2 mM MgCl 2 , 0.1 mM leupeptin, 0.1 mM pepstatin and 0.2 mM phenylmethylsulfonyl fluoride. Assays were performed in 96 well plates (Wallec) and employed solutions composed of varying concentrations of a compound of Formula I in 100% DMSO.
  • radiolabeled farnesyl pyrophosphate [1- 3 H] , specific activity 15-30 Ci/mmol, final concentration 0.12 ⁇ M
  • biotinyl) -Ahe-Tyr-Lys-Cys- Val-Ile-Met peptide final concentration 0.1 ⁇ M
  • the enzyme reaction was started by addition of 40-fold purified rat brain farnesyl protein transferase. After incubation at 37°C for 30 minutes, the reaction was 12612
  • ⁇ 24* terminated by diluting the reaction 2.5-fold with a stop buffer containing 1.5 M magnesium acetate, 0.2 M H 3 P0 4 , 0.5% BSA, and strepavidin beads (Amersham) at a concentration of 1.3 mg/mL. After allowing the plate to settle for 30 minutes at room temperature, radioactivity was quantitated on a microBeta counter (model 1450, Wallec) .
  • Compounds of Formula I show IC 50 values of 0.5 nM to 80 ⁇ M (see data table) in this assay and are thus valuable inhibitors of protein: farnesyl transferase enzyme which may be used in the medical treatment of tissue proliferative diseases, including cancer and restenosis.
  • the compounds of the present invention can be prepared and administered in a wide variety of oral, rectal and parenteral dosage forms.
  • the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally.
  • the compounds of the present invention can be administered by inhalation, for example, intranasally.
  • the compounds of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt of a compound of Formula I.
  • pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from 5 or 10 to about 70 percent of the active compound.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation” is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included.
  • Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
  • Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions.
  • liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
  • viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the pharmaceutical preparation is preferably in unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsules, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 100 mg preferably 0.5 mg to 100 mg according to the particular application and the potency of the active component.
  • the composition can, if desired, also contain other compatible therapeutic agents.
  • the compounds utilized in the pharmaceutical methods of this invention are administered at the initial dosage of about 0.01 mg/kg to about 20 mg/kg daily.
  • a daily dose range of about 0.01 mg/kg to about 10 mg/kg is preferred.
  • the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art.
  • treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached.
  • the total daily dosage may be divided and administered in portions during the day, if desired.
  • Fmoc-NH 2 -Rink resin (0.25 mmol scale) was treated with 20% piperidine in NMP to afford NH 2 -Rink resin.
  • Sequential coupling of Fmoc-protected Ser(OBn) and Tyr(OBn) (DCC and HOBT in NMP) and Fmoc deprotection (20% piperidine in NMP) reactions were run using a 4-fold excess of reagents in the coupling steps and traditional resin washing cycles to afford
  • Fmoc-Ser(OBn) , Fmoc-Tyr(OBn) , and Cbz-His are sequentially coupled using the deprotection and coupling conditions described in Example 1. Cleavage from the resin is accomplished by treatment with CF 3 S0 2 H for the PAM supported tripeptide or with 50% TFA in DCM for the HMP supported tripeptide. Chromatography as in Example 1 provides Cbz-His-Tyr(OBn) -Ser(OBn) as its TFA salt upon - 31 - lyophilization. See also Example 7 for a solution phase method.
  • Step 3 Fmoc-His (Tr) -Tyr(OBn) -CQ 2 CH 2 CH 2 TMS To a solution of HOBT (2.6 g, 19.3 mmol) in DMF
  • Step 5 Fmoc-His (2-Cl-Tr Resin) -Tyr(OBn) -CQ 2 CH 2 CH 2 TMS To a suspension of Fmoc-His-Tyr(OBn) - C0 2 CH 2 CH 2 TMS
  • the suspension was agitated by shaking for 18 hours, filtered, washed sequentially with a 2:1 mixture of dioxane and 10% citric acid (3x 10 mL) , dioxane:MeOH (3x 10 mL) , dioxane (3x 10 mL) , and CHC1 3 (3x 10 mL) to provide BnNHCO-His (2-Cl-Tr-Resin) -Tyr(OBn) .
  • the BnNHCO-His (2-Cl-Tr-Resin) -Tyr(OBn) was suspended in DMF (10 mL) and treated with a carbodiimide coupling reagent such as DIC (0.2 g, 1.6 mmol) and HOBT (0.22 g, 1.6 mmol) .
  • a carbodiimide coupling reagent such as DIC (0.2 g, 1.6 mmol) and HOBT (0.22 g, 1.6 mmol) .
  • 3-phenoxypropylamine (0.24 g, 1.6 mmol) was added.
  • the resulting mixture was shaken 18 hours before filtering the resin and washing with DMF (3x) and CHC1 3 (3x) .
  • the resin was suspended in DMF (10 mL) and the carbodiimide/HOBT/3-phenoxypropylamine coupling reaction was repeated. After 18 hours, the resin was filtered and washed with 10 mL each of MeOH (2x
  • BnNHCO-His (2-Cl-Tr-Resin) -Tyr(OBn) -CONH(CH 2 ) 3 OPh The highly substiuted dipeptide was cleaved from the resin by treatment with 40% TFA in DCM, shaking for 1 hour at room temperature. The supernate, containing the free dipeptide, was filtered away from the resin and the resin was washed with DCM (6x) . The combined supernate and washings were concentrated in vacuo to provide BnNHCO-His-Tyr(OBn) -CONH(CH 2 ) 3 OPh*TFA.
  • Example 4 The method described in Example 4 may be employed in simultaneous multiple syntheses using the Diversomer apparatus described by S.H. DeWitt, et al. , Proc. Natl. Acad. Sci. USA. £0:6909 (1993) .
  • Fmoc-D-His (2-C1- Tr Resin) -Tyr(OBn) -C0 2 iPr prepared according to from Example 3 by substituting Fmoc-D-His (Tr) for Fmoc- His (Tr) in Step 3, (100-200 mg) is placed in each of 40 gas dispersion tubes, and the tubes are placed in the Diversomer apparatus.
  • the sequential deprotection and coupling reactions described in Example 4 are followed, employing the following acyiating agents and amines in various combinations: Acyiating agents Amines
  • BnNHCO-D-His-Tyr CONHOBn ES-MS 647 (m+1) 53.
  • BnNHCO-D-His-Tyr (OBn) CONHCH 2 CH 2 CH 2 OPh ES-MS 675 (m+1) 12612
  • Step 2 Tyr(OBn) -Ser(OBn) -C0 2 Me*TFA Boc-Tyr(OBn) -Ser(OBn) -C0 2 Me (from Step 1 above,
  • Step 3 Cbz-His-Tyr(OBn) -Ser(OBn) -CQ 2 Me To a solution of Cbz-His (1.00 g, 3.47 mmol) in
  • Step 2 Cbz-D-His (Tr) -Tyr (OBn) - Ser (OBn) - CC Me
  • Example 6 According to Example 6, Step 3, by substituting Cbz-D-His (Tr) for Cbz-His and Tyr(OBn) -Ser(OBn) - C0 2 Me-HCl for Tyr(OBn) -Ser(OBn) -C0 2 Me-TFA, the title compound was obtained as a white solid, mp 78-88°C; FAB-MS 976 (m+1) .
  • Step 3 Cbz-D-His-Ty (OBn) -Ser(OBn) -CQ 2 Me
  • Example 6 by substituting D-Ser(OBn) -C0 2 Me-TFA for Ser(OBn) -C0 2 Me-TFA in Step 1, the title compound was obtained, mp 168-170°C; FAB-MS 734 (m+1) .
  • EXAMPLE 10 N- fof-Methyl-N- fN- f (phenylmethoxy) carbonyl! -L-histidyll - 0- (phenylmethyl) -DL-tyrosyl! -0- (phenylmethyl) -L-serine. methyl ester ⁇ Cbz-His-DL- ( ⁇ -Me)Tyr(OBn) -Ser(OBn) -CQ 2 Me ⁇ According to Example 6, by substituting Boc-DL-
  • Example 6 by substituting Boc-Tyr(OBn) -Ser(OBn) -CONHEt for Boc-Tyr(OBn) - Ser(OBn) -C0 2 Me in Step 2, the title compound was obtained, mp 182-188°C; FAB-MS 747 (m+1) .
  • Step 1 Cbz-His (1-Me) Benzyl chloroformate (0.24 mL, 1.7 mmol) was added dropwise to a slurry of 1-methyl-L-histidine (0.25 g, 1.5 mmol) in THF (5 mL) and saturated aqueous NaHC0 3 (5 mL) at 0°C. The mixture was allowed to warm to room temperature and stirred overnight. The mixture was concentrated and diluted with H 2 0, washed with ether, and the pH adjusted to 6-7 with IN HC1. The mixture was concentrated, then diluted with CHC1 3 (150 mL) and MeOH (15 mL) , and stirred for 1 hour. The mixture was dried (MgS0 4 ) and concentrated to provide 0.48 g of the title compound which was used without further purification.
  • Step 2 Cbz-His (1-Me) -Tyr(OBn) -Ser(OBn) -C0 2 Me
  • Example 6 by substituting Boc- homoTyr(OBn) for Boc-Tyr(OBn) in Step 1, and substituting Cbz-D-His for Cbz-His in Step 3, the title compound was obtained; ES-MS 748 (m+1) .
  • Step 1 Fmoc-His (Tr) -Tyr(OBn) -Ser(OBn) -C0 2 Me According to Example 13, Step 2, by substituting
  • Step 2 His (Tr) -Tyr(OBn) -Ser(OBn) -C0 2 Me Piperidine (4.0 mL) was added to a slurry of
  • Step 3 BnNHCO-His (Tr) -Tyr(OBn) -Ser(OBn) -CQ 2 Me
  • Benzyl isocyanate (0.053 mL, 0.43 mmol) was added in one portion to a solution of His(Tr) -Tyr(OBn) - Ser(OBn) -C0 2 Me (from Step 2 above, 0.33 g, 0.39 mmol) in EtOAc (5 mL) . The resulting slurry was stirred for 3 hours at room temperature, then concentrated to yield the title compound (0.4 g) , which was used without further purification.
  • Step 4 BnNHCO-His-Tyr(OBn) -Ser(OBn) -CO-.Me According to Example 8, by substituting BnNHCO-
  • Example 8 by substituting PhCH 2 CH 2 CO-His(Tr) -Tyr(OBn) -Ser(OBn) -C0 2 Me for Cbz-D- His (Tr) -Tyr(OBn) -Ser(OBn) -C0 2 Me, the title compound was obtained, mp 193-196.5°C; ES-MS 732 (m+1) .
  • Example 6 According to Example 6, Step 3, by substituting Tyr(OBn) -C0 2 Me-TFA for Tyr(OBn) -Ser(OBn) -C0 2 Me-TFA, the title compound was obtained as a white powder, mp 145-148°C; CI-MS 557 (m+1) .
  • Example 7 by substituting Cbz-His- Tyr(OBn) -C0 2 Me for Cbz-His-Tyr(OBn) -Ser(OBn) -C0 2 Me, the title compound was obtained as a white powder, mp 79-92°C; CI-MS 543 (m+1) .
  • Step 3 Cbz-His -Tyr(OBn) -CONHCH 2 CH 2 OBn
  • Example 6 by substituting 2- (phenyl- methoxy)ethyla ine for Ser(OBn) -TFA and omitting Et 3 N in Step 1 and by substituting Cbz-D-His for Cbz-His in Step 3, the title compound was prepared, mp 161-165°C; FAB-MS 676 (m+1) .
  • Example 20 by substituting Boc- ( ⁇ !-Me)Tyr(OBn) for Boc-Tyr(OBn) , the title compound was obtained, mp 66-78°C; ES-MS 690 (m+1) .
  • EXAMPLE 23 N- (2-Phenylethyl) -N a - fN- f (phenylmethoxy) carbonyl! - L-histidyl! -0- (phenylmethyl) -L-tyrosinamide ⁇ Cbz-His-Tyr(OBn) -C0NHCH CH 2 Ph) According to Example 19, Step 3, by substituting
  • Example 19 by substituting Pyr-C0 2 Me for 2- (phenylmethoxy) ethylamine, the title compound was obtained as a white solid, mp 180-182.5°C (dec) ; FAB-MS 705 (m+1) .
  • Boc-Tyr(OBn) -CONH(CH ) 3 OPh 2- (Phenylmethoxy) ethylamine (0.81 g, 5.4 mmol) was added to a premixed solution of EDAC (1.2 g, 6.5 mmol), HOBT (0.87 g, 6.5 mmol), and Boc-Tyr(OBn) -OH (2.0 g, 5.4 mmol) in dry DMF (15 mL) . The resulting mixture was stirred for 18 hours at room temperature.
  • Step 4 D-His(Tr) -Tyr(OBn) -CONH(CH 2 ) 3 OPh Fmoc-D-His(Tr) -Tyr(OBn) -CONH(CH 2 ) 3 OPh (from Step 3 above, 1.0 g, 0.99 mmol) in CH 2 C1 2 (5 mL) was treated with piperidine (0.18 g, 2.1 mmol) .
  • Step 5 (4-Et0Ph)NHC0-D-His(Tr) -Tyr(OBn) -CONH(CH ) 3 OPh D-His(Tr) -Tyr(OBn) -CONH(CH 2 ) 3 OPh (from Step 4 above, 0.55 g, 0.7 mmol) in CH 2 C1 2 (5 mL) was treated with 4-ethoxyphenyl isocyanate (0.1 g, 0.7 mmol) . The resulting mixture was stirred 1 hour at room temperature. Concentrated in vacuo.
  • Step 6 (4-EtOPh)NHCO-D-His-Tyr(OBn) -CONH(CH 2 ) 3 OPh
  • 4-EtOPh)NHCO-D-His(Tr) -Tyr(OBn) -CONH(CH 2 ) 3 OPh (from Step 5 above, 0.5 g, 0.52 mmol) in MeOH (5 mL) was treated with Pyridine-HCl (catalytic) . The resulting mixture was stirred at 65°C for 6 hours.
  • Example 25 According to Example 25, Step 4, by substituting Fmoc-D-His (Tr) -Tyr(OBn) -CONH(CH 2 ) 3 (2-MeOPh) for Fmoc-D- His (Tr) -Tyr(OBn) -CONH(CH 2 ) 3 OPh, the title compound was obtained as a white foam; ES-MS 798 (m+1) .
  • Example 25 by substituting BocTyr(OBn) -CONH(CH 2 ) 2 Ph for BocTyr(OBn) -CONH(CH 2 ) 3 OPh, the title compound was obtained as a white solid; CI-MS 375 (m+1) .
  • Step 4 (4-MePh)SQ -D-His(Tr) -Tyr(OBn) -CO (4-Bn- piperazin-l-yl) Fmoc-D-His-Tyr(OBn) -CONH(CH 2 ) 3 OPh, (0.7 g,

Abstract

Novel inhibitors of protein:farnesyl transferase enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in controlling tissue proliferative diseases, including cancer and restenosis.

Description

SUBSTITUTED DI- AND TRIPEPTIDE INHIBITORS OF PROTEIN:FARNESYL TRANSFERASE
FIELD OF THE INVENTION
The present invention pertains to a number of compounds which can be used in the medicinal field to treat, prophylactically or otherwise, uncontrolled or abnormal proliferation of human tissues. More specifically, the present invention pertains to a number of compounds which act to inhibit the farnesyl transferase enzyme that has been determined to activate ras proteins which in turn activate cellular division and are implicated in cancer and restenosis.
BACKGROUND OF THE INVENTION
Ras protein (or p21) has been examined extensively because mutant forms are found in 20% of most types of human cancer and greater than 50% of colon and pancreatic carcinomas (Gibbs J.B., Cell, 65:1 (1991), Cartwright T. , et al. , Chimica Ocrαi. 10.:26 (1992)) . These mutant ras proteins are deficient in the capability for feedback regulation that is present in native ras and this deficiency is associated with their oncogenic action since the ability to stimulate normal cell division can not be controlled by the normal endogenous regulatory cofactors. The recent discovery that the transforming activity of mutant ras is critically dependent on post-translational modifications (Gibbs J., et al. , Microbiol. Rev.. 53.:171 (1989)) has unveiled an important aspect of ras function and identified novel prospects for cancer therapy. In addition to cancer, there are other conditions of uncontrolled cellular proliferation that may be related to excessive expression and/or function of native ras proteins. Post surgical vascular restenosis is such a condition. The use of various surgical revascularization techniques such as saphenous vein bypass grafting, endarterectomy and transluminal coronary angioplasty is often accompanied by complications due to uncontrolled growth of neointimal tissue, known as restenosis. The biochemical causes of restenosis are poorly understood and numerous growth factors and protooncogenes have been implicated (Naftilan A.J., et al. , Hypertension, 13.:706 (1989) and J. Clin. Invest., 83.:1419; Gibbons G.H. , et al. , Hypertension. .14:358 (1989) ; Satoh T. , et al. , Mollec. Cell. Biol.. 11:3706 (1993)) . The fact that ras proteins are known to be involved in cell division processes makes them a candidate for intervention in many situations where cells are dividing uncontrol- lably. In direct analogy to the inhibition of mutant ras related cancer, blockade of ras dependant processes has the potential to reduce or eliminate the inappropriate tissue proliferation associated with restenosis, particularly in those instances where normal ras expression and/or function is exaggerated by growth stimulatory factors.
Ras functioning is dependent upon the modification of the proteins in order to associate with the inner face of plasma membranes. Unlike other membrane- associated proteins, ras proteins lack conventional transmembrane or hydrophobic sequences and are initially synthesized in a cytosol soluble form. Ras protein membrane association is triggered by a series of posttranslational processing steps that are signaled by a carboxyl terminal amino acid consensus sequence that is recognized by protein:farnesyl transferase. This consensus sequence consists of a cysteine residue located four amino acids from the carboxyl terminus, followed by two lipophilic amino acids and the C-terminal residue. The sulfhydryl group of the cysteine residue is alkylated by farnesyl pyrophosphate in a reaction that is catalyzed by protein:farnesyl transferase. Following prenylation, the C-terminal three amino acids are cleaved by an endoprotease and the newly exposed alpha-carboxyl group of the prenylated cysteine is methylated by a methyl transferase. The enzymatic processing of ras proteins that begins with farnesylation enables the protein to associate with the cell membrane. Mutational analysis of oncogenic ras proteins indicate that these posttranslational modifications are essential for transforming activity. Replacement of the consensus sequence cysteine residue with other amino acids gives a ras protein that is no longer farnesylated, fails to migrate to the cell membrane and lacks the ability to stimulate cell proliferation (Hancock J.F., et al., Cell. 57:1617 (1989); Schafer W.R. , et al. , Science. 245:379 (1989); Casey P.J. , Proc. Natl. Acad. Sci. USA. .86:8323 (1989) ) .
Recently, protein:farnesyl transferases (PFTs, also referred to as farnesyl:protein transferases) have been identified and a specific PFT from rat brain was purified to homogeneity (Reiss Y., et al., Bioch. Soc. Trans. , 2J:487-88 (1992)) . The enzyme was charac¬ terized as a heterodimer composed of one alpha-subunit (49 kDa) and one beta-subunit (46 kDa) , both of which are required for catalytic activity. High level expression of mammalian PFT in a baculovirus system and purification of the recombinant enzyme in active form has also been accomplished (Chen W.-J., et al., J. Biol. Chem.. 268.:9675 (1993)). 2612
- 4 -
In light of the foregoing, the discovery that the function of oncogenic ras proteins is critically dependent on their posttranslational processing provides a means of cancer chemotherapy through inhibition of the processing enzymes. The identification and isolation of a protein:farnesyl transferase that catalyzes the addition of a farnesyl group to ras proteins provides a promising target for such intervention. Recently it has been determined that prototypical inhibitors of PFT can inhibit ras processing and reverse cancerous morphology in tumor cell models (Kohl N.E., et al., Science. 260:1934 (1993); James G.L., et al. , Science. 2^fJ:1937 (1993); Garcia A.M., et al. , J. Biol. Chem.. 268:18415 (1993)). Thus, it is possible to prevent or delay the onset of cellular proliferation in cancers that exhibit mutant ras proteins by blocking PFT. By analogous logic, inhibition of PFT would provide a potential means for controlling cellular proliferation associated with restenosis, especially in those cases wherein the expression and/or function of native ras is overstimulated.
PCT Application O91/16340 discloses cysteine containing tetrapeptide inhibitors of PFT of the formula CAAX.
European Patent Application 0461869 discloses cysteine containing tetrapeptide inhibitors of PFT of the formula Cys-Aaa1-Aaa2-Xaa.
European Patent Application 0520823 discloses cysteine containing tetrapeptide inhibitors of PFT of the formula Cys-Xaa1-dXaa2-Xaa3.
European Patent Application 0523873 discloses cysteine containing tetrapeptide inhibitors of PFT of the formula Cys-Xaa1-Xaa2-Xaa3. 2612
- 5 -
European Patent Application 0528486 discloses cysteine containing tetrapeptide amides inhibitors of PFT of the formula Cys-Xaa1-Xaa2-Xaa3-NRR1.
European Patent Application 0535730 discloses pseudotetrapeptide inhibitors of PFT of the following two formulas:
European Patent Application 0535731 (US 5,238,922) discloses esters of pseudotetrapeptide inhibitors of PFT of the formula:
European Patent Application 0482539 discloses tachykinin antagonists of the formula:
- 6 -
European Patent Application 0457195 discloses endothelin antagonists of the formula:
US 4,022,759 discloses tripeptide antagonists of luteinizing hormone releasing factor of the formula A-R-^Tyr(benzyl) -Ser(benzyl) -R2, wherein one of the definitions of R-j^ is His (benzyl) .
Compounds disclosed in the above references do not disclose or suggest a novel combination of structural variations found in the present invention described hereinafter. All cited references are hereby incorporated by reference.
SUMMARY OF THE INVENTION
Accordingly, the present invention is a substituted di- or tripeptide compound of Formula I:
wherein: n = 1 or 2;
A = COR3, C02R3, CONHR3, CSR3, C(S)OR3, C(S)NHR3, CF3S02, aryl-S02, or alkyl-S02, wherein R3 is alkyl, (CH2)m-cycloalkyl, (CH2)m-aryl,
(CH2)m-heteroaryl, or (CH2)mO-alkyl, and m = 0, 1, 2, or 3; R = independently H or Me; Y = independently H or Me; Z = independently H or Me;
R1 = H, CO-aryl, (CH2)m-aryl, 0(CH2)m-cycloalkyl,
0(CH2)m-aryl, or 0(CH2)m-heteroaryl, wherein m is as defined above and R1 is located at either the meta or para position; X = one to four substituents, including H, alkyl, CF3, F, Cl, Br, I, HO, MeO, N02, NH2, N(Me)2, 0P03H2, or
R2 = NR(CH2)nC02R3, NR(CH2)nCONHR3, NR(CH2)nR3, NR(CH2)n+1OR4, NR(CH2)n+1SR4, NRCH(COR5) (CH2)n-heteroaryl, NRCH(C0R5) (CH2)nOR3,
NRCH(C0R3) (CH )nSRJ, or —R wherein R, R3, and n are as defined above, R4 = H or R3, and R5 = OH, NH2, OR3, or NHR3; an optical isomer, diastereomer, or a pharmaceutically acceptable salt thereof.
The present invention is also directed to the use of a compound of Formula I, or a pharmaceutically acceptable salt therefrom, to inhibit the activity of a protein:farnesyl transferase enzyme as a method for treating tissue proliferative diseases.
A further embodiment of the present invention is the use of a pharmaceutical composition including an effective amount of a compound of Formula I as a method for the treatment of cancer. 12612
- 8 -
A still further embodiment of the present invention is the use of a pharmaceutical composition including an effective amount of a compound of Formula I as a method for the treatment of restenosis. A still further embodiment of the present invention is a pharmaceutical composition for administering an effective amount of a compound of Formula I in unit dosage form in the treatment methods mentioned above. A final embodiment of the present invention pertains to methods for the preparation of compounds of Formula I by solid phase synthesis, solution phase synthesis, and simultaneous multiple syntheses using a multiple simultaneous synthesis apparatus.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
In the compounds of Formula I, the term "alkyl" means a straight or branched hydrocarbon radical having from 1 to 6 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and the like. The term "cycloalkyl" means a saturated hydrocarbon ring which contains from 3 to 10 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, and the like, unsubstituted or substituted by an alkyl or aryl group. The term "aryl" means an aromatic ring which is a phenyl, 5-fluorenyl, 1-naphthyl or 2-naphthyl group, unsubstituted or substituted by 1 to 3 substituents selected from alkyl, 0- lkyl and S-alkyl, O-aryl, OH, SH, F, Cl, Br, I, CF3, N02, NH2, NHCH3, N(CH3)2, NHCO-alkyl, (CH2)mC02H, (CH2)mC02-alkyl, (CH2)mS03H, (CH2)mP03H2, (CH2)mP03(alkyl)2, (CH2)mS02NH2, and (CH2)mS02NH-alkyl wherein alkyl is defined as above and m = 0, 1, 2, or 3.
The term "heteroaryl" means a heteroaromatic ring which is a 2- or 3-thienyl, 2- or 3-furanyl, 2- or 3-pyrrolyl, 2-, 3- or 4-pyridyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl group, unsubstituted or with 1 or 2 substituents from the group of substituents described above for aryl.
The following table provides a list of abbreviations and definitions thereof used in the present invention.
TABLE OF ABBREVIATIONS
If the optical activity of the amino acid is other than L(S), the amino acid or abbreviation is preceded by the appropriate configuration D(R) or DL(RS) . 12612
-10-
Abbreviation Amino Acid (continued)
Tyr Tyrosine
Val Valine
Abbreviation* Modified and Unusual Amino Acid Aaa-C02R An amino acid ester, for examples: Gly-C02Bn is Glycine, benzyl ester; Ser(OBn) -C02Me is O-Benzyl-serine, methyl ester.
Aaa-CONHR An amino acid amide, for examples: Gly-CONHBn is Glycine, N-benzyl amide; Ser(OBn) -CONHEt is O-Benzyl-serine, N-ethyl amide; Tyr(OBn) -CONHCH2CH2OBn is O-Benzyl- tyrosine, N- (2- (phenylmethoxy)ethyl) amide.
3Hyp 3-Hydroxyproline
4Hyp 4-Hydroxyproline
Hey Homocysteine
Nva Norvaline
Nle Norleucine
Orn Ornithine
Bal Beta-alanine (or 3-aminopropionic acid)
Abu 4-Aminobutyric acid Ahe 7-Aminoheptanoic acid Acp 6-Aminocaproic acid Aoc 8-Aminooctanoic acid Apn 5-Aminopentanoic acid Bpa (4-Benzoylphenyl)alanine Chx 3-Cyclohexylalanine (or Hexahydrophenylalanine)
Cit Citrulline
If the optical activity of the amino acid is other than L(S) , the amino acid or abbreviation is preceded by the appropriate configuration D(R) or DL(RS) . 12612
-11-
Abbreviation* Modified and Unusual Amino Acid (continued) His (1-Me) 1-Methyl-histidine (or N(τ) -Methyl- histidine) His(Tr) 1-Triphenylmethyl-histidine (or N(τ) -Trityl-histidine) homoPhe 2-Amino-4-phenylbutanoic acid (or Homophenylalanine) homoTyr 2-Amino-4- (4-hydroxyphenyl)butanoic acid (or Homotyrosine) homoTyr(OBn) 2-Amino-4- [4- (phenylmethoxy)phenyl] - butanoic acid (or O-Benzyl- homotyrosine) 3- (1' -NaphthyDalanine 3- (2' -NaphthyDalanine Penicillamine (3-Benzyloxyphenyl) lanine 3- (1, 1 'Biphen-4-yl)alanine (or 4-Phenyl-phenylalanine) Phenylglycine
2-Amino-3- (3-pyridyl) -propanoic acid (or 3-Pyridylalanine) 0-Benzyl-serine 0-Benzyl-threonine
1,2,3,4-Tetrahydro-3-isoquinoline- carbσxylic acid 0-Methyl-tyrosine 0-Ethyl-tyrosine 0-Benzyl-tyrosine 2-Amino-3- (4-benzyloxyphenyl) - 2-methyl-propionic acid (or α-Methyl- 0-benzyl-tyrosine)
(N-Me)Tyr(OBn) N-Methyl-0-benzyl- yrosine Trp(For) Nιn-Formyltryptophan
If the optical activity of the amino acid is other than L(S) , the amino acid or abbreviation is preceded by the appropriate configuration D(R) or DL(RS) . -12-
Abbreviation Mercapto Acids
Maa Mercaptoacetic acid
Mba 4-Mercaptobutyric acid
Mpa 3-Mercaptopropionic acid
Abbreviation Protecting Group
Ac Acetyl
Ada 1-Adamantyl acetic acid
Adoc Adamantyloxycarbonyl Bn Benzyl
MeBn 4-Methylbenzyl
Cbz Benzyloxycarbonyl
2-Br-Cbz ortho-Bromobenzy1oxycarbonyl
2-Cl-Cbz ortho-Chiorobenzy1oxycarbonyl Bom Benzyloxymethy1
Boc tertiary Butyloxycarbonyl
Dnp 2, -Dinitrophenyl
For For yl
Fmoc 9-Fluorenylmethy1oxycarbonyl N02 Nitro
TMS Trimethylsilyl
Tos 4-Toluenesulfonyl (tosyl)
Tr Triphenylmethyl (trityl)
Abbreviation Solvents and Reagents
HOAc Acetic acid
CF3S02H Trifluoromethanesulfonic acid
DCM Dichloromethane
DCC N,N' -Dicyclohexylcarbodiimide
DIC N,N' -Diisopropylcarbodiimide
DIEA N,N-Diisopropylethylamine
DMAP 4-Dimethylaminopyridine
DMF N,N' -Dimethylformamide
EDAC N-Ethyl-N' -Dimethylaminopropyl- carbodiimide
EtOAc Ethyl acetate -13-
Abbreviation Solvents and Reagents
Et20 Diethyl ether
HC1 Hydrochloric acid
HF Hydrofluoric acid
HOBT 1-Hydroxybenzotriazole
KOH Potassium hydroxide
MeCN Acetonitrile
MeOH Methanol
NHOS N-Hydroxysuccinimide
NMP N-Methylpyrrolidone iPrOH iso-Propanol
TBAF Tetra n-Butylammonium Fluoride
TFA Trifluoroacetic acid
Abbreviation Solid Phase Peptide Synthesis Resins HMP Resin 4- (Hydroxymethyl) -phenoxymethyl- polystyrene resin
MBHA Resin Methylbenzhydrylamine resin PAM Resin 4- (Hydroxymethyl) - phenylacetamidomethyl-polystyrene resin
2-Cl-Tr Resin 2-Chlorotrityl-polystyrene resin NH2-Rink Resin 4- (amino- (2 ' ,4' -dimethoxy- phenyl)methyl) -phenoxymethyl- polystyrene resin
Abbreviation Biological Reagents
FPP Farnesyl pyrophosphate
PFT Protein:farnesyl transferase
DTT Dithiothreitol
BSA Bovine serum albumin -14-
Abbreviation Miscellaneous COR3 0
CR3
CONHR3 0
CNHR3
CSR-
CR-
C(S)OR3
COR-
C(S)NHR3
CNHR3
0
CH(COR5) (CH2)nOR- (CH2)nCNHR3
R5
CH(COR5) (CH2)n- heteroaryl 0=C
I
C- (CH2)n- heteroaryl H
R5
CH(COR5) (CH2)nOR- 0=C
I
C- (CH2)nOR3
I H
CH(COR5) (CH2)nOR2 0=C
I
C- (CH,)nSR-
I
H
0
CO (4-Bn-piperazin-l-yl) — N Γ~ N— CH2Ph v_y 1
- 15 -
Preferred compounds of Formula I consist of compounds of Formula II below:
wherein:
A' = C02R3, CONHR3, C(S)NHR3, or aryl-S02, wherein R3 is alkyl, (CH2)m-cycloalkyl, (CH2)m-aryl, (CH2)m-heteroaryl, and m = 0, 1, 2, or 3;
R = independently H or Me; Y = independently H or Me; Z = independently H or Me;
R1 = (CH2)m-aryl, 0(CH2)m-aryl, OP03H2, or CH2P03H2, wherein m is as defined above;
R^ = NR(CH2)20R4, NR(CH2)2SR4, NRCH(COR5) CH2OR3,
/ \
NRCH(COR3)CH,SRJ, or , N N—CH2Ph
\_/ wherein R, R3, and n are as defined above, R4 = H or R3, and R5 = OH, NH2, OR3, or NHR3; an optical isomer, diastereomer, or a pharmaceutically acceptable salt thereof.
Other preferred compounds of the present invention are those of Formula I as defined above wherein A is C02R3 or CONHR3; or as defined above in Formula I wherein at least one of Y and Z is Me; or as defined above in Formula I wherein R2 is (CH2)2OR4 or CH(COR5)CH2OR3; or as defined above in Formula I 2612
- 16 - wherein A is CONHR3, R2 is (CH2)20R4, and at least one of Y and Z is Me.
The most preferred compounds of Formula I include the following: Cbz-His-Tyr(OBn) -Ser(OBn) -C02Me;
Cbz-His-Tyr(OBn) -Ser(OBn) -CONH2;
Cbz-His-Tyr(OBn) -Ser(OBn) -CONHEt;
Cbz-His-Tyr(OBn) -Ser(OBn) ;
Cbz-His-Tyr(OBn) -D-Ser(OBn) -C02Me; Cbz-D-His-Tyr(OBn) -Ser(OBn) -CONH2;
Cbz-D-His-Tyr(OBn) -Ser(OBn) -CONHEt;
Cbz-D-His-Tyr(OBn) -Ser(OBn) -C02Me;
Cbz-D-His-Tyr(OBn) -Ser(OBn) ;
Cbz-His(l-Me) -Tyr(OBn) -Ser(OBn) -C02Me; Cbz-His(l-Me) -Tyr(OBn) -Ser(OBn) -CONH2;
Cbz-His(l-Me) -Tyr(OBn) -Ser(OBn) -CONHEt;
Cbz-His(l-Me) -Tyr(OBn) -Ser(OBn) ;
Cbz-D-His(l-Me) -Ty (OBn) -Ser(OBn) -C02Me;
Cbz-D-His(l-Me) -Tyr(OBn) -Ser(OBn) -CONH2; Cbz-D-His(l-Me) -Tyr(OBn) -Ser(OBn) -CONHEt;
Cbz-D-His(l-Me) -Tyr(OBn) -Ser(OBn) ;
Cbz-His- (α-Me)Tyr(OBn) -Ser(OBn) -C02Me;
Cbz-His- (o;-Me)Tyr(OBn) -Ser(OBn) -CONH2;
Cbz-His- (Q!-Me)Tyr(OBn) -Ser(OBn) -CONHEt; Cbz-His- (α_-Me)Tyr(OBn) -Ser(OBn) ;
Cbz-His-D- (cϋ-Me)Tyr(OBn) -Ser(OBn) -C02Me;
Cbz-His-D- (o;-Me)Tyr(OBn) -Ser(OBn) -CONH2;
Cbz-His-D- (Qt-Me)Tyr(OBn) -Ser(OBn) -CONHEt;
Cbz-His-D- (ot-Me)Tyr(OBn) -Ser(OBn) ; Cbz-D-His-homoTyr(OBn) -Ser(OBn) -C02Me;
Cbz-His-Phe (4-Ph) -Ser(OBn) -C02Me;
Cbz-D-His-Phe(4-Ph) -Ser(OBn) -C02Me;
Cbz-His-Tyr(OBn) -Pyr-C02Me;
Cbz-D-His-Tyr(OBn) -Pyr-C02Me; Cbz-His-Tyr(OBn) -CONHCH2CH2OBn;
Cbz-D-His-Tyr(OBn) -CONHCH2CH2OBn; Cbz-His- (N-Me)Tyr(OBn) -CONHCH2CH2OBn;
Cbz-D-His- (N-Me)Tyr(OBn) -CONHCH2CH2OBn;
Cbz-His-Tyr(OBn) -CONH(CH2)2Ph;
Cbz-D-His-Tyr(OBn) -CONH(CH2) 2Ph; .Cbz-His-Tyr(OBn) -Gly-C02Bn;
Cbz-D-His-Tyr(OBn) -Gly-C02Bn;
Cbz-His-Tyr(OBn) -Gly-CONHBn;
Cbz-D-His-Tyr(OBn) -Gly-CONHBn;
BnNHCO-His-Tyr(OBn) -Ser(OBn) -C02Me; BnNHCO-His-Tyr(OBn) -Ser(OBn) -CONH2;
BnNHCO-His-Tyr(OBn) -Ser(OBn) -CONHEt;
BnNHCO-His-Tyr(OBn) -Ser(OBn) ;
BnNHCO-His-Tyr(OBn) -CONHCH2CH2OBn;
BnNHCO-His-Tyr(OBn) -CONHCH2CH2CH2OPh; BnNHCO-D-His-Tyr(OBn) -Ser(OBn) -C02Me;
BnNHCO-D-His-Tyr(OBn) -Ser(OBn) -CONH2;
BnNHCO-D-His-Tyr(OBn) -Ser(OBn) -CONHEt;
BnNHCO-D-His-Tyr(OBn) -Ser(OBn) ;
BnNHCO-D-His-Tyr(OBn) -CONHCH2CH2OBn; BnNHCO-D-His-Tyr(OBn) -CONHCH2CH2CH2OPh;
Cbz-His-Tyr(OBn) -CON(Me) CH2CH2OBn;
(4-EtOPh)NHCO-D-His-Tyr(OBn) -CONH(CH2)3OPh;
PhCH2CO-D-His-Tyr(OBn) -CONH(CH2)3- (2-MeOPh) ;
(4-Ph0Ph)NHC0-D-His-Tyr(0Bn) -COHN(CH2) 2Ph; and (4-MePh)S02-D-His-Tyr(OBn) -CO(4-Bn- piperazin-1-yl) .
GENERAL METHODS FOR THE PREPARATION, EVALUATION AND USE OF COMPOUNDS OF FORMULA I
The compounds of Formula I may be prepared by solid phase peptide synthesis on a peptide synthesizer, for example, an Applied Biosystems 431A peptide synthesizer using activated esters or anhydrides of Boc or Fmoc protected amino acids, acid chlorides, isocyanates, isothiocyanates, etc., on PAM, MBHA, or NH2-Rink resins with solution phase modifications to the carboxyl terminus as appropriate. Methodology for the solid phase synthesis of peptides is widely known to those skilled in the art thereof (see, for example: J.M. Stewart and J.D. Young in Solid Phase Peptide Synthesis: Pierce Chemical Co.; Rockford, IL (1984); Fields G.B. and Noble R.L. , Int. J. Peptide Protein Res.. 3^:161-214 (1990)) . Additionally, the compounds of Formula I may also be prepared by conventional solution peptide synthesis, substituting amines, acid chlorides, isocyanates, etc, for amino acid derivatives where appropriate. Methods for solution phase synthesis of peptides are widely known to those skilled in the art (see, for example, M. Bodanszky, Principles of Peptide Synthesis. Springer-Verlag (1984)) .
Finally, the compounds of Formula I may be prepared by simultaneous multiple solid phase syntheses using an apparatus described by S. H. DeWitt, et al. , Proc. Natl. Acad. Sci. USA. 9.0:6909 (1993), and referred to by the trademark, Diversomer™, both trademark and apparatus being owned in whole by the Warner-Lambert Company. The multiple solid phase synthesis apparatus is currently the subject of now abandoned US Serial 07/958,383 filed October 8, 1992 and pending continuation-in-part US Serial 08/012,557 filed February 2, 1993.
For example (Scheme I below), Fmoc-D-His-Tyr(OBn) - C02-CH2CH2Si (CH3)3 is linked to 2-Cl-Tr resin using a sterically hindered amine such as DIEA as an HC1 scavenger, the Fmoc protecting group is removed with piperidine, the resulting free amino terminus is acylated with a series of isocyanates, isothiocyanates, activated esters, acid chlorides and the like, the TMS-ethyl ester is cleaved with TBAF, the resulting 12612
- 19 - free carboxy terminus is activated with a carbodiimide reagent such as EDAC, DCC, or DIC, the activated carboxyl group is reacted with alcohols such as HOBT, NHOS, or pentachlorophenol to give an activated ester, the activated ester is reacted with a series of amines and the resulting array of compounds of Formula I is cleaved from the resin by with hot HOAc or by treatment with TFA at room temperature.
For all three synthetic methods described above appropriate consideration is given to protection and deprotection of reactive functional groups and to the sequence of synthetic steps. Knowledge of the use of common protecting groups and strategy for the assembly of complex organic molecules are within the usual realm of expertise of a practitioner of the art of organic chemistry (see, for example: T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Chemistry. John Wiley and Sons (1991); E.J. Corey and X.-M. Cheng, The Logic of Chemical Synthesis. John Wiley and Sons (1989)).
The homogeneity and composition of the resulting compounds is verified by reverse phase-high pressure liquid chromatography (RP-HPLC) , capillary electrophoresis, thin layer chromatography (TLC) , proton nuclear magnetic resonance spectrometry (NMR) , amino acid analysis, fast atom bombardment mass spectrometry (FAB-MS) and electrospray mass spectrometry (ES-MS) . 2612
-20- SCHEME I: Multiple Simultaneous Synthesis Method
1. TBAF
2. EDAC, HOBT
3. Five amines
40 Compounds of Formula I
12612
- 21 -
The compounds of Formula I are capable of further forming both pharmaceutically acceptable acid addition and/or base salts. All of these forms are within the scope of the present invention. Pharmaceutically acceptable acid addition salts of the compounds of Formula I include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate, n-methyl glucamine (see, for example, Berge S.M., et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science. £6:1-19 (1977)). The acid addition salts of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. Preferably a compound of Formula I can be converted to an acidic salt by treating with an aqueous solution of the desired acid, such that the resulting pH is less than 4. The solution can be passed through a C18 cartridge to absorb the compound, washed with copious amounts of water, the compound eluted with a polar organic solvent such as, for example, methanol, acetonitrile, and the like, and isolated by concentrating under reduced pressure followed by lyophilization. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner or as above. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention. Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N' -dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge S.M., et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science. 6£: 1 - 19 (1977)).
The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. Preferably, a compound of Formula I can be converted to a base salt by treating with an aqueous solution of the desired base, such that the resulting pH is greater than 9. The solution can be passed through a C18 cartridge to absorb the compound, washed with copious amounts of water, the compound eluted with a polar organic solvent such as, for example, methanol, acetonitrile and the 2612
- 23 - like, and isolated by concentrating under reduced pressure followed by lyophilization. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner or as above. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention.
Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R(D) or S(L) configuration. The present invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof.
The PFT inhibitory activity of compounds of Formula I was assayed in 30 mM potassium phosphate buffer, pH 7.4, containing 7 mM DTT, l.'2 mM MgCl2, 0.1 mM leupeptin, 0.1 mM pepstatin and 0.2 mM phenylmethylsulfonyl fluoride. Assays were performed in 96 well plates (Wallec) and employed solutions composed of varying concentrations of a compound of Formula I in 100% DMSO. Upon addition of both substrates, radiolabeled farnesyl pyrophosphate ( [1-3H] , specific activity 15-30 Ci/mmol, final concentration 0.12 μM) and (biotinyl) -Ahe-Tyr-Lys-Cys- Val-Ile-Met peptide (final concentration 0.1 μM) , the enzyme reaction was started by addition of 40-fold purified rat brain farnesyl protein transferase. After incubation at 37°C for 30 minutes, the reaction was 12612
■24* terminated by diluting the reaction 2.5-fold with a stop buffer containing 1.5 M magnesium acetate, 0.2 M H3P04, 0.5% BSA, and strepavidin beads (Amersham) at a concentration of 1.3 mg/mL. After allowing the plate to settle for 30 minutes at room temperature, radioactivity was quantitated on a microBeta counter (model 1450, Wallec) . Compounds of Formula I show IC50 values of 0.5 nM to 80 μM (see data table) in this assay and are thus valuable inhibitors of protein: farnesyl transferase enzyme which may be used in the medical treatment of tissue proliferative diseases, including cancer and restenosis.
IC50 Values for Selected Compounds of Formula I Against PFT
Example Number IC50 (μM)
1 4 . 4 4 1. 0 5 (3 ) 2 . 1 5 (4 ) 7 . 3
0 Values for Selected Compounds of Formula I Against PFT
Example Number IC50 (μM)
5 (61) 7.2 5 (62) 1.5
5 (63) 1.0
5 (64) 1.7
5 (69) 0.48
5 (79) 3.0 5 (80) 1.6
6 0.42
7 0.26
8 0.074
9 0.27 10 0.10
11 0.17
12 0.028
13 0.083 15 30 16 0.60
17 0.039
18 0.82
19 0.31 21 0.31 22 0.37
23 1.9 ■ 26 -
IC50 Values for Selected Compounds of Formula I Against PFT (cont'd)
Example Number
24 25 28 29
The compounds of the present invention can be prepared and administered in a wide variety of oral, rectal and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt of a compound of Formula I.
For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.
In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
The powders and tablets preferably contain from 5 or 10 to about 70 percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration. For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify. Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection liquid preparations can be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsules, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 100 mg preferably 0.5 mg to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents. In therapeutic use as inhibitors of PFT, the compounds utilized in the pharmaceutical methods of this invention are administered at the initial dosage of about 0.01 mg/kg to about 20 mg/kg daily. A daily dose range of about 0.01 mg/kg to about 10 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
The following nonlimiting examples illustrate the inventors' preferred methods for preparing the compounds of the invention. For added clarity, complex chemical names describing compounds of Formula I are followed by structural abbreviations, which are shown in braces, wherein the structural elements are as defined in the Table of Abbreviations above.
EXAMPLE 1 Nα- fN- TN- r (Phenylmethoxy)carbonyll -L-histidyll - 0- (phenylmethyl) -L-tyrosyll -O- (phenylmethyl) - L-serinamide (Cbz-His-Tyr(OBn) -Ser(OBn) -C0NH2}
Using an ABI model 431A solid phase peptide synthesizer, Fmoc-NH2-Rink resin (0.25 mmol scale) was treated with 20% piperidine in NMP to afford NH2-Rink resin. Sequential coupling of Fmoc-protected Ser(OBn) and Tyr(OBn) (DCC and HOBT in NMP) and Fmoc deprotection (20% piperidine in NMP) reactions were run using a 4-fold excess of reagents in the coupling steps and traditional resin washing cycles to afford
Tyr(OBn) -Ser(OBn) -CONH2-Rink resin. This dipeptide 12612
- 30 - resin was transferred to an uninst umented reaction vessel and treated with a 4-fold excess of Cbz-His, DCC, and HOBT in DMF, shaking overnight at room temperature. After removal of excess reagents, the resulting substituted tripeptide was cleaved from the resin by treatment with 50% TFA in DCM at room temperature for 2.5 hours. Evaporation of solvents and purification by reversed phase chromatography (C18-column, eluted with a 20-70% gradient of MeCN in water (both solvents acidified with 0.1% TFA) afforded Cbz-His-Tyr(OBn) -Ser(OBn) -CONH2 as its TFA salt upon lyophilization. ES-MS: 719 (m+1) .
Using analogous methods the following most preferred compounds of Formula I with carboxamides at the C-terminus may be prepared:
Cbz-D-His-Tyr(OBn) -Ser(OBn) -CONH2;
Cbz-His (1-Me) -Tyr(OBn) -Ser(OBn) -CONH2;
Cbz-D-His (1-Me) -Tyr(OBn) -Ser(OBn) -CONH2;
Cbz-His-DL- (Qj-Me)Tyr(OBn) -Ser(OBn) -CONH2; BnNHCO-His-Tyr(OBn) -Ser(OBn) -CONH2; and
BnNHCO-D-His-Tyr(OBn) -Ser(OBn) -CONH2.
EXAMPLE 2 N- fN- fN- Γ (Phenylmethoxy)carbonyll -L-histidyll - O- (phenylmethyl) -L-tyrosyll -0- (phenylmethyl) -L-serine {Cbz-His-Tyr(OBn) -Ser(OBn) )
Beginning with PAM resin or HMP resin, Fmoc-Ser(OBn) , Fmoc-Tyr(OBn) , and Cbz-His are sequentially coupled using the deprotection and coupling conditions described in Example 1. Cleavage from the resin is accomplished by treatment with CF3S02H for the PAM supported tripeptide or with 50% TFA in DCM for the HMP supported tripeptide. Chromatography as in Example 1 provides Cbz-His-Tyr(OBn) -Ser(OBn) as its TFA salt upon - 31 - lyophilization. See also Example 7 for a solution phase method.
Using analogous methods the following most preferred compounds of Formula I with a free carboxyl terminus may be prepared:
Cbz-D-His-Tyr(OBn) -Ser(OBn) ;
Cbz-His (1-Me) -Tyr(OBn) -Ser(OBn) ;
Cbz-D-His(l-Me) -Tyr(OBn) -Ser(OBn) ;
Cbz-His-DL- (oj-Me)Tyr(OBn) -Ser(OBn) ; BnNHCO-His-Tyr(OBn) -Ser(OBn) ; and
BnNHCO-D-His-Tyr(OBn) -Ser(OBn) .
EXAMPLE 3 Solid phase supported N- TN- f (9H-Fluoren-9- ylmethoxy) carbonyl1 -L-histidyll -O- (phenylmethyl) - L-tyrosine, 2-trimethylsilylethyl ester {Fmoc- His (2-Cl-Tr Resin) -Tyr(OBn) -CQ CH2CH2TMS) Step 1: Boc-Tyr(OBn) -CQ2CH2CH2TMS
2-Trimethylsilyl ethanol (2.6 g, 22.6 mol) was added to a premixed solution of EDAC (4.3 g,
22.6 mmol), DMAP (0.5 g) , and Boc-Tyr(OBn) -OH (7.0 g, 18.8 mmol) in dry THF (25 mL) . .The resulting mixture was stirred for 18 hours at room temperature. The solution was diluted with 1:1 EtOAc:Et20 (40 mL) , washed with saturated aqueous NaHC03 (2 x 10 mL) and with saturated aqueous NaCl (2 x 10 mL) , dried (MgS04) , filtered and concentrated in vacuo to provide an oil which was further purified by flash chromatography (Si02, EtOAc:hexane eluent) to give the pure TMS-ethyl ester as an oil; λH NMR (HCDC13) : δ 0.04 (s, 9H) , 1.43 (s, 9H) , 3.03 (m, 2H) , 4.22 (m, 2H) , 4.51 (m, IH) , 4.95 (m, IH) , 5.05 (s, 2H) , 6.85-7.48 (m, 9H) . 95/12612
- 32 -
Step 2: Tyr(OBn) -C0 CH2CH2TMS
Eighty percent TFA in CH2C12 (20 mL, v/v) was added to an ice-cooled solution of Boc-Tyr(OBn) - C02CH2CH2TMS (14.8 g, 31.4 mmol) in CH2C12 (40 mL) . The resulting mixture was stirred for 1.0 minute before concentrating in vacuo. The procedure was repeated once more, and the resulting residue was diluted with CH2C12 and saturated aqueous NaHC03. The resulting mixture was filtered through celite. The organic layer was then separated, washed with saturated aqueous NaCl, and dried (MgS04) . Filtration and concentration in vacuo provided an oil which was further purified by flash chromatography (Si02, CHCl3:MeOH eluent) to give the desired product; XH NMR (HCDC13) : δ 0.06 (s, 9H) , 1.68 (br s, 2H) ,
2.85-3.03 (m, 2H) , 3.67 (m, IH) , 4.22 (m, 2H) , 5.05 (s, 2H) , 6.91-7.45 (m, 9H) .
Step 3: Fmoc-His (Tr) -Tyr(OBn) -CQ2CH2CH2TMS To a solution of HOBT (2.6 g, 19.3 mmol) in DMF
(10 mL) was added Fmoc-His (Tr) ( 10.0 g, 16.1 mmol) followed by EDAC (3.7 g, 19.3 mmol) . The mixture was stirred at room temperature for 20 minutes before adding a solution of Tyr(OBn) -C02CH2CH2TMS (from Step 2 above, 5.8 g, 16.1 mmol) in DMF (10 mL) . The mixture was stirred overnight at room temperature before partitioning between a mixture of water and 1:1 Et20:EtOAc (50 mL) . The layers were separated, and the organic phase was washed with saturated aqueous NaCl (4 x 20 mL) and dried (MgS04) . Filtration and concentration in vacuo provided an oil which was further purified by flash chromatography (Si02, CHCl3:MeOH eluent) to give the protected His-Tyr dipeptide; FAB-MS 974 (m+1) . Step 4: Fmoc-His-Tyr(OBn) -CQ CH2CH2TMS
Fmoc-His (Tr) -Tyr(OBn) -C02CH2CH2TMS (from Step 3 above, 5.0 g, 5.1 mmol) was treated with pyridineoHCl (1.0 g) in MeOH (20 mL) . The mixture was allowed to stir 8 hours at 65°C. The solution was concentrated in vacuo, and the residue was dissolved in CH2C12, washed with H20 (lx) , saturated aqueous NaHC03 (2x) , and dried (MgS04) . Filtration and concentration in vacuo provided an oil which was further purified by flash chromatography (Si02, CHCl3:MeOH eluent) to give Fmoc-His-Tyr(OBn) -C02CH2CH2STMS as a white solid; FAB-MS 731 (m+1) .
Step 5: Fmoc-His (2-Cl-Tr Resin) -Tyr(OBn) -CQ2CH2CH2TMS To a suspension of Fmoc-His-Tyr(OBn) - C02CH2CH2TMS
(from Step 4 above, 5.3 g, 7.3 mmol) in CHC13 (20 mL) was added 2-chloroltrityl chloride resin (Novabiochem) (7.1 g) followed by DIEA (0.96 g, 7.4 mmol) . The resulting mixture was subjected to brief sonication to disperse the resin and then agitated on a shaker for 2.0 hours. The modified resin was collected by filtration, washed with DMF (2x) , MeOH (2x) , CHC12 (2x) , and dried in vacuo for 18 hours to yield 10.5 g (loading corresponds to approximately 1 mmol/g resin) .
EXAMPLE 4 N- r3-Phenoxypropyll -0- (phenylmethyl) -Nα- fN- r r (phenylmethyl)amino1 carbonyll -L- istidyll -L- tyrosinamide .BnNHCO-His-Tyr(OBn) -CONH(CH2)3OPh} Fmoc-His (2-Cl-Tr-Resin) -Tyr(OBn) -C02CH2CH2TMS
(from Example 3 above, 2.0 g) was suspended in 20% piperidine in DMF. The resulting suspension was subjected to sonication for 10 minutes and then agitated by shaking for 30 minutes. The resin was filtered and washed with DMF (3x) . The resin was again subjected to the same reaction conditions for an additional 20 minutes. The resin was filtered and washed with DMF (4x) and CHC13 (3x) to provide His (2-Cl-Tr-Resin) -Tyr(OBn) -C02CH2CH2TMS which was suspended in DCM (10 mL) , agitated by shaking for 30 minutes, treated with benzyl isocyanate (1.1 g,
8.0 mmol), and agitated for an additional 30 minutes. The resin was filtered, washed with DCM (3x) , resuspended in DCM, and the benzyl isocyanate treatment was repeated. The resin was filtered and washed with DMF (2x) and CHC13 (5x) to give BnNHCO-His (2-Cl-Tr-
Resin) -Tyr(OBn) -C02CH2CH2TMS which was next suspended in a mixture of 4:3 dioxane:MeOH (14 mL) and treated with 1.0 M TBAF in THF (2.0 mL, 2.0 mmol) . The suspension was agitated by shaking for 18 hours, filtered, washed sequentially with a 2:1 mixture of dioxane and 10% citric acid (3x 10 mL) , dioxane:MeOH (3x 10 mL) , dioxane (3x 10 mL) , and CHC13 (3x 10 mL) to provide BnNHCO-His (2-Cl-Tr-Resin) -Tyr(OBn) . The BnNHCO-His (2-Cl-Tr-Resin) -Tyr(OBn) was suspended in DMF (10 mL) and treated with a carbodiimide coupling reagent such as DIC (0.2 g, 1.6 mmol) and HOBT (0.22 g, 1.6 mmol) . The resulting mixture was stirred 30 minutes and 3-phenoxypropylamine (0.24 g, 1.6 mmol) was added. The resulting mixture was shaken 18 hours before filtering the resin and washing with DMF (3x) and CHC13 (3x) . The resin was suspended in DMF (10 mL) and the carbodiimide/HOBT/3-phenoxypropylamine coupling reaction was repeated. After 18 hours, the resin was filtered and washed with 10 mL each of MeOH (2x) , DCM (3x) , DMF (2x) , MeOH (2x) , and CHC13 (2x) to give
BnNHCO-His (2-Cl-Tr-Resin) -Tyr(OBn) -CONH(CH2)3OPh. The highly substiuted dipeptide was cleaved from the resin by treatment with 40% TFA in DCM, shaking for 1 hour at room temperature. The supernate, containing the free dipeptide, was filtered away from the resin and the resin was washed with DCM (6x) . The combined supernate and washings were concentrated in vacuo to provide BnNHCO-His-Tyr(OBn) -CONH(CH2) 3OPh*TFA. The product was partitioned between water and DCM, and both layers were treated dropwise with saturated aqueous NaHC03 until the aqueous layer remained basic. The layers were separated, and the organic phase was washed with saturated aqueous NaCl and dried (MgS04) . Filtration and concentration yielded BnNHCO-His-Tyr(OBn) - CONH(CH2)3OPh; ES-MS 675 (m+1) .
EXAMPLE 5 Multiple. Simultaneous Solid Phase Synthesis
The method described in Example 4 may be employed in simultaneous multiple syntheses using the Diversomer apparatus described by S.H. DeWitt, et al. , Proc. Natl. Acad. Sci. USA. £0:6909 (1993) . Fmoc-D-His (2-C1- Tr Resin) -Tyr(OBn) -C02iPr, prepared according to from Example 3 by substituting Fmoc-D-His (Tr) for Fmoc- His (Tr) in Step 3, (100-200 mg) is placed in each of 40 gas dispersion tubes, and the tubes are placed in the Diversomer apparatus. The sequential deprotection and coupling reactions described in Example 4 are followed, employing the following acyiating agents and amines in various combinations: Acyiating agents Amines
1) benzyl isocyanate 1) 3-phenox propylamine
2) p-toluenesulfonyl chloride 2) 2- (phenylmethoxy)ethyl amine
3) cyclohexyl isocyanate 3) 2- [ (phenylmethyl) - thioj -ethylamine
4) phenyl isocyanate 4) 4-phenylbutylamine
5) i-propyl isocyanate 5) 3- (2-methoxyphenyl) - propylamine
6) n-butyl isocyanate 6) 1-benzyl piperazine 7) 4-chlorophenyl isocyanate 7) o-benzyl-hydroxylamine
8) 1-napthyl isocyanate 8) methionine methyl ester
9) 3-methoxypropyl isocyanate 9) benzylamine
10) 4-ethoxyphenyl isocyanate 10) 2-phenylethylamine
11) 2-phenethyl isocyante 2612
-36-
12) 3-phenylpropionyl chloride
14) phenylacetyl chloride
15) 4-phenoxyphenyl isocyanate
16) benzyl chloroformate 17) (trans) -2-phenylcyclopropyl isocyanate
18) 1-adamantyl chloroformate
Array 1. Following cleavage from the resin and work-up as described in Example 4, the following substituted dipeptides (1-40) of Formula I are prepared:
1. PhNHCO - D - Hi ε - Tyr ( OBn ) - CONHCH2CH2OBn
2. PhNHCO-D-His-Tyr(OBn) - CONHCH2CH2SBn ES-MS 677 (m+1)
3. PhNHCO-D-His-Tyr(OBn) -CONHCH2CH2CH2OPh ES-MS 661 (m+1)
4. BuNHCO-D -His -Tyr (OBn) -CONH (CH2)4Ph ES-MS 639 (m+1) 5. BuNHCO-D-Hiε-Tyr (OBn) -CO (4-Bn-piperazin- l-yl) ES-MS 665 (m)
6. (4-MePh)S02-D-His-Tyr(0Bn) -C0NHCH2CH2Ph ES-MS 666 (m+1)
7. (4-MePh)Sθ2-D-His-Tyr(OBn) -CONHCH2CH2SBn ES-MS 712 (m+1)
8. CF3S02-D-His- yr(OBn) -CONH-Met-CC^Me 9. CF3S02-D-His-Tyr(0Bn) -CONHCH2CH2CH2- (2-MeO-Ph)
10. CF3S02-D-His-Tyr (OBn) -CO(4-Bn-piperazin-l-yl)
11. BnNHCO - D - Hi s - Tyr ( OBn ) C0NHCH2CH2Ph
12. MeO (CH2) 3NHCO-D-Hiε-Tyr (OBn) CONHOBn
13. MeO (CH2) 3NHCO-D-His-Tyr (OBn) CONHCH2CH2CH2OPh 14. MeO (CH2)3NHCO-D-Hiε-Tyr (OBn) CONH (CH2)3-
(2-MeO-Ph)
15. BnNHCO-D-His-Tyr(OBn)CONHCH2Ph ES-MS 631 (m+1)
16. (4-ClPh)NHCO-D-Hiε-Tyr(OBn)CONHCH2CH2OBn ES-MS 695 (m+1)
17. 1-Napthyl-NHCO-D-His-Tyr (OBn) CONHOBn ES-MS 683 (m+1) 18. l-Napthyl-NHCO-D-His-Tyr(OBn)CONH-Met-Cθ2Me ES-MS 723 (m+1)
19. (4-ClPh)NHC0-D-His-Tyr(0Bn)C0NH(CH2)4Ph ES-MS 693 (m+1)
20. (4-ClPh)NHC0-D-His-Tyr(0Bn)C0NHCH2Ph ES-MS 651 (m+1)
21. Bn0C0-D-His-Tyr(0Bn)C0NHCH2CH20Bn ES-MS 676 (m+1)
22. 1 - adamanty 1 - OCO - D - Hi s - Tyr ( OBn ) CONHCH2CH2SBn 23. Bn0C0-D-His-Tyr(0Bn)C0NHCH2CH2CH20Ph ES-MS 676 (m+1)
24. 1-adamantyl-OCO-D-His- Tyr (OBn) C0NHCH2CH2CH2CH2Ph
25. BnOCO-D-His-Tyr (OBn) CO (4-Bn-piperazin- l-yl) ES-MS 700 (m) 26. PhCH2C0-D-His-Tyr(0Bn)C0NHCH2CH2Ph ES-MS 630 (m+1)
27. PhCH2CH2NHCO-D-Hiε-Tyr(OBn)CONHCH2CH2SBn ES-MS 705 (m+1) 2612
-37-
28. PhCH2CH2NHCO-D-His -Tyr (OBn) CONH- et -
CO->Me ES-MS 701 (m+1)
29. PhOT2CH2NHCO -D - His -Tyr (OBn) CONH (CH2)3-
(2-MeO-Ph) * ES-MS 703 (m+1) 30. PhCH2CO-D-His-Tyr (OBn) CO (4-Bn-piperazin- l-yl) ES-MS 684 (m)
31. (t-2-Ph-c-propyl) -NHCO-D-His-
Tyr (OBn) C0NHCH2CH2Ph ES-MS 671 (m+1)
32. (t-2-Ph-c-propyl) -NHCO-D-Hiε- Tyr (OBn) CONHOBn ES-MS 673 (m+1)
33. c-hexyl-NHCO-D-His-Tyr(OBn)
CONH(CH2)3OPh ES-MS 666 (m+1)
34. c-hexyl-NHCO-D-His-Tyr (OBn) CONH (CH2)3-
(2-MeO-Ph) ES-MS 681 (m+1) 35. c-hexyl-NHCO-D-Hiε-Tyr(OBn)CONHCH2Ph ES-MS 623 (m+1)
36. PhCH2CH2CO-D-His-Tyr(OBn)CONHCH2CH2OBn ES-MS 674 (m+1)
37. PhCH2CH2CO-D-His-Tyr (OBn) CONHOBn ES-MS 646 (m+1)
38. (CH3)2CHNHCO-D-His-Tyr(OBn)CONH-Met-
CC^Me ES-MS 639 (m+1) 39. PhCH2CH2CO -D- His -Tyr (OBn) CONH (CH2)3Ph ES-MS 672 (m+1)
40. (CH3)2CHNHCO-D-His-Tyr(OBn)CONHCH2Ph ES-MS 583 (m+1)
Array 2. Following cleavage from the resin and work-up as described in Example 4, the following substituted dipeptides (41-80) of Formula I are prepared:
41. n-BuNHCO-D-Hiε-Tyr(OBn) -C0NHCH2CH20Bn ES-MS 641 (m+1)
42. n-BuNHCO-D-His-Tyr(OBn) -C0NHCH2CH2SBn ES-MS 657 (m+1)
43. n-BuNHCO-D-His-Tyr(OBn) -CONHCH2CH2CH2OPh ES-MS 641 (m+1)
44. PhNHCO -D -His -Tyr (OBn) - CONHCH2CH2CH2CH2Ph ES-MS 659 (m+1) 45. PhNHCO- D -His -Tyr (OBn) -CO (4-Bn-piperazin-l-yl) ES-MS 685 (m)
46. (4-PhOPh)NHCO-D-His-Tyr(OBn) -CONHCH2CH2Ph ES-MS 723 (m+1)
47. (4-PhOPh)NHCO-D-His-Tyr(OBn) -CONHCH2CH2SBn ES-MS 769 (m+1)
48. (4-MePh)Sθ2-D-His-Tyr(OBn) -CONH- et -COjMe ES-MS 708 (m+1) 49. (4 -MePh) SC^-D-His-Tyr (OBn) -CONHCH2CH2CH2- (2-MeO-Ph)
50. (4-MePh)S02-D-His-Tyr (OBn) -CO (4-Bn-piperazin- l-yl) ES-MS 720 (m)
51. MeO ( CH2 ) 3NHCO - D - Hi ε - Tyr ( OB ) CONHCH2CH2Ph
52. BnNHCO-D-His-Tyr (OBn) CONHOBn ES-MS 647 (m+1) 53. BnNHCO-D-His-Tyr (OBn) CONHCH2CH2CH2OPh ES-MS 675 (m+1) 12612
-38-
54. BnNHCO-D-His-Tyr (OBn) CONH (CH2) 3 -
(2-MeO-Ph) ES-MS 689 (m+1)
55. MeO (CH2) 3NHCO-D-His -Tyr (OBn) CONHCH2Ph
56. l-napthyl-NHCO-D-Hiε-Tyr(OBn)CONHCH2CH2OBn ES-MS 711 (m+1) 57. (4 -ClPh)NHCO-D-His -Tyr (OBn) CONHOBn
58. (4-ClPh)NHCO-D-His-Tyr(OBn)CONH-
Met-CC^Me ES-MS 707 (m+1)
59. 1 -napthyl -NHCO-D -Hi ε-
Tyr (OBn) CONHCH2CH2CH2CH2Ph ES-MS 709 (m+1) 60. 1 -napthyl -NHCO-D -His -Tyr (OBn) CONHCH2Ph
61. (4-EtOPh)NHCO-D-His-
Tyr (OBn) CONHCH2CH2OBn ES-MS 705 (m+1)
62. BnOCO-D-Hiε-Tyr (OBn) CONHCH2CH2SBn 63. (4-EtOPh)NHCO-His- Tyr (OBn) CONHCH2CH2CH2OPh ES-MS 705 (m+1)
64. BnOCO-D-His -Tyr (OBn) CONHCH2CH2CH2CH2Ph
65. (4 -EtOPh)NHCO-D-His-Tyr (OBn) CO (4-Bn- piperazin-l-yl) ES-MS 729 ( )
66. PhCH2CO-D-Hiε-Tyr (OBn) CONHCH2CH2Ph ES-MS 659 (m+1) 67. PhCH2CO-D-Hiε-Tyr(OBn)CONHCH2CH2SBn ES-MS 676 (m+1)
68. PhCH2CO-D-His-Tyr(OBn)CONH-Met-C -.Me
69. PhCH2CO-D-His-Tyr (OBn) CONH (CH2)3-
(2-MeO-Ph) ES-MS 674 (m+1)
70. PhCH2CH2NHCO-D-Hiε-Tyr (OBn) CO (4 -Bn- piperazin-1-yl) ES-MS 713 (m)
71. c-hexyl-NHCO-D-His-
Tyr (OBn) CONHCH2CH2Ph ES-MS 637 (m+1)
72. c-hexyl-NHCO-D-His-Tyr (OBn) CONHOBn ES-MS 639 (m+1)
73. (t-2-Ph-c-propyl) -NHCO-D-His- Tyr (OBn) CONH (CH2)3OPh ES-MS 701 (m+1)
74. (t-2-Ph-c-propyl) -NHCO-D-His- Tyr(OBn)CONH(CH2)3- (2-MeO-Ph)
75. (t-2-Ph-c-propyl) -NHCO-D-Hiε-
Tyr (OBn) CONHCH2Ph ES-MS 657 (m+1) 76. (CH3)2CHNHCO-D-Hiε-
Tyr (OBn) CONHCH2CH2OBn ES-MS 627 (m+1)
77. (CH3)2CHNHCO-D-H s-Tyr (OBn) CONHOBn ES-MS 599 (m+1)
78. PhCH2CH2CO -D- His -Tyr (OBn) CONH -Me - CC^Me ES-MS 686 (m+1)
79. (CH3)2CHNHCO-D-His- Tyr (OBn) CONHCH2CH2CH2CH2Ph ES-MS 625 (m+1)
80. PhCH2CH2CO-D-His-Tyr(OBn)CONHCH2Ph ES-MS 630 (m+1) 12612
- 39 -
EXAMPLE 6 N- fN- fN- r (Phenylmethoxy) carbonyll -L-histidyll - 0- (phenylmethyl) -L-tyrosyll -0- (phenylmethyl) -L-serine. methyl ester {Cbz-His-Tyr(OBn) -Ser(OBn) -C02Me} Step 1: Boc-Tyr(OBn) -Ser(OBn) -C02Me
To a solution of Boc-Tyr(OBn) (1.88 g, 6.50 mmol) in EtOAc (30 mL) at 0°C was added HOBT hydrate (1.19 g, 7.80 mmol) followed by DCC (1.61 g, 7.80 mmol) . A solution of Ser(OBn) -C02Me-TFA (2.1 g, 6.50 mmol) in EtOAc (20 mL) was added followed by Et3N (1.09 mL,
7.80 mmol) . The mixture was allowed to warm to room temperature and stirred overnight. The mixture was filtered, diluted with EtOAc, and washed twice with saturated aqueous NaHC03, brine, dried over MgS04, and concentrated. Flash chromatography (40% EtOAc/hexane) gave 2.67 g (73%) of the title compound as a white solid, mp 81-84°C.
Step 2 : Tyr(OBn) -Ser(OBn) -C02Me*TFA Boc-Tyr(OBn) -Ser(OBn) -C02Me (from Step 1 above,
2.64 g, 4.69 mmol) was dissolved in CH2C12 (15 mL) , cooled to 0°C and TFA (5 mL) was added. The solution was warmed to room temperature and stirred for 4 hours.
The solution was concentrated, taken up in CH2C12 and reconcentrated twice. The resulting oil was triturated with ether to provide 2.7 g of the title compound as a white solid.
Step 3 : Cbz-His-Tyr(OBn) -Ser(OBn) -CQ2Me To a solution of Cbz-His (1.00 g, 3.47 mmol) in
DMF (15 mL) at 0°C was added HOBT (0.64 g, 4.16 mmol) and DCC (0.86 g, 4.16 mmol) . Tyr(OBn) -Ser(OBn) - C02Me-TFA (from Step 2 above, 2.0 g, 3.47 mmol) was added followed by Et3N (0.58 mL, 4.16 mmol) . The mixture was allowed to warm to room temperature and stirred overnight. The mixture was filtered and the 12612
- 40 - filtrate was diluted with CHC13, washed twice with saturated aqueous NaHC03, brine, dried over MgS04, and concentrated. Flash chromatography (2-5% MeOH/CHCl3) gave 2.14 g of the title compound as a white solid, mp 175-176°C; FAB-MS 734 (m+1); Anal. Calc. for C41H43N508:
C, 67.11; H, 5.91; N, 9.54; Found: C, 66.96; H, 6.01; N, 9.41.
EXAMPLE 7
N- TN- TN- r (Phenylmethoxy) carbonyl] -L-histidyll -
O- (phenylmethyl) -L-tyrosyll -O- (phenylmethyl) -L-serine
(Cbz-His-Tyr(OBn) -Ser(OBn) }
To a solution of Cbz-His-Tyr(OBn) -Ser(OBn) -C02Me (from Example 6 above, 2.02 g, 2.75 mmol) in THF
(50 mL) and MeOH (15 mL) at 0°C was added 0.IN LiOH (30.3 mL, 3.03 mmol) . The solution was stirred for 6 hours at 0°C, then concentrated. Water was added and the pH was adjusted to 4-5 with IN HC1. The mixture was filtered, and the solid was collected and dried to provide 1.55 g (78%) of the title compound as a white solid, mp 187-192°C; ES-MS 720 (m+1); Anal. Calc. for C40H41N5O8 • 1.5H20:
C, 64.33; H, 5.94; N, 9.38; Found: C, 64.29; H, 5.73; N, 9.15.
EXAMPLE 8 N- TN- fN- T (Phenylmethoxy) carbonyl! -D-histidyll - O- (phenylmethyl) -L-tyrosyll -0- (phenylmethyl) -L-serine. methyl ester {Cbz-D-His-Tyr(OBn) -Ser(OBn) -C02Me} Step 1: Tyr(OBn) -Ser(OBn) -C02Me-HCl
A solution of Boc-Tyr(OBn) -Ser(OBn) -C02Me (from Example 6, Step 1 above, 9.90 g, 17.6 mmol) in EtOAc was cooled to 0°C. Anhydrous HC1 gas was bubbled through the cold solution for 5 minutes. The solution was allowed to warm to room temperature and stirred 2612
- 41 - overnight . The solution was concentrated, taken up in EtOAc and reconcentrated to provide 8 . 75 g of the title compound as a foam; CI -MS 463 (m+1) .
Step 2 : Cbz-D-His (Tr) -Tyr (OBn) - Ser (OBn) - CC Me
According to Example 6, Step 3, by substituting Cbz-D-His (Tr) for Cbz-His and Tyr(OBn) -Ser(OBn) - C02Me-HCl for Tyr(OBn) -Ser(OBn) -C02Me-TFA, the title compound was obtained as a white solid, mp 78-88°C; FAB-MS 976 (m+1) .
Step 3: Cbz-D-His-Ty (OBn) -Ser(OBn) -CQ2Me
A solution of Cbz-D-His (Tr) -Tyr(OBn) -Ser(OBn) -
C02Me (from Step 2 above, 0.27 g, 0.28 mmol) in HOAc:H20 (4:1, 2 mL) was stirred at 80°C for 5 minutes, then cooled to room temperature. The solution was partitioned between EtOAc and saturated aqueous NaHC03.
The organic layer was washed with brine, dried (MgS04) , and concentrated. Flash chromatography (2-5% MeOH:CHCl3) yielded 0.10 g of the title compound as a foam; FAB-MS 734 (m+1) .
EXAMPLE 9 N- fN- fN- f (Phenylmethoxy) carbonyll -L-histidyll -O- (phenylmethyl) -L-tyrosyll -0- (phenylmethyl) -D-serine. methyl ester {Cbz-His-Tyr(OBn) -D-Ser(OBn) -CQ2Me}
According to Example 6, by substituting D-Ser(OBn) -C02Me-TFA for Ser(OBn) -C02Me-TFA in Step 1, the title compound was obtained, mp 168-170°C; FAB-MS 734 (m+1) . EXAMPLE 10 N- fof-Methyl-N- fN- f (phenylmethoxy) carbonyl! -L-histidyll - 0- (phenylmethyl) -DL-tyrosyl! -0- (phenylmethyl) -L-serine. methyl ester {Cbz-His-DL- (α-Me)Tyr(OBn) -Ser(OBn) -CQ2Me} According to Example 6, by substituting Boc-DL-
(α-Me)Tyr(OBn) for Boc-Tyr(OBn) in Step 1, the title compound was obtained; FAB-MS 748 (m+1) .
EXAMPLE 11 N-Ethyl-NQ- fN- fN- f (phenylmethoxy) carbonyl! -L-histidyll - O- (phenylmethyl) -L-tyrosyl! -O- (phenylmethyl) -L- serinamide {Cbz-His-Tyr(OBn) -Ser(OBn) -CONHEt}
According to Example 6, by substituting Boc-Tyr(OBn) -Ser(OBn) -CONHEt for Boc-Tyr(OBn) - Ser(OBn) -C02Me in Step 2, the title compound was obtained, mp 182-188°C; FAB-MS 747 (m+1) .
EXAMPLE 12 N-Ethyl-NQ.- fN- fN- f (Phenylmethoxy) carbonyl! -D-histidyl! - O- (phenylmethyl) -L-tyrosyl! -O- (phenylmethyl) -
L-serinamide {Cbz-D-His-Tyr(OBn) -Ser(OBn) -CONHEt} According to Example 6, by substituting Boc- Tyr(OBn) -Ser(OBn) -CONHEt for Boc-Tyr(OBn) -Ser(OBn) - C02Me in Step 2 and Cbz-D-His for Cbz-His in Step 3, the title compound was obtained, mp 193-196°C; ES-MS 747 (m+1) .
EXAMPLE 13 N- fN- fl-Methyl-N- f (phenylmethoxy) carbonyl!1-L- histidyll -
O- (phenylmethyl) -L-tyrosyll -O- (phenylmethyl) -L-serine. methyl ester (Cbz-His (1-Me) -Tyr(OBn) -Ser(OBn) -C02MeI
Step 1: Cbz-His (1-Me) Benzyl chloroformate (0.24 mL, 1.7 mmol) was added dropwise to a slurry of 1-methyl-L-histidine (0.25 g, 1.5 mmol) in THF (5 mL) and saturated aqueous NaHC03 (5 mL) at 0°C. The mixture was allowed to warm to room temperature and stirred overnight. The mixture was concentrated and diluted with H20, washed with ether, and the pH adjusted to 6-7 with IN HC1. The mixture was concentrated, then diluted with CHC13 (150 mL) and MeOH (15 mL) , and stirred for 1 hour. The mixture was dried (MgS04) and concentrated to provide 0.48 g of the title compound which was used without further purification.
Step 2: Cbz-His (1-Me) -Tyr(OBn) -Ser(OBn) -C02Me
To a slurry of Cbz-His (1-Me) (from Step 1 above, 0.36 g, 1.2 mmol), Tyr(OBn) -Ser(OBn) -C02Me-HC1 (from Example 8, Step 1 above, 0.60 g, 1.2 mmol), DCC
(0.30 g, 1.4 mmol), and HOBT (0.19 g, 1.4 mmol) in CH2C12 was added Et3N (0.17 mL, 1.2 mmol) and the mixture was stirred overnight at room temperature. The mixture was diluted with CHC13, washed with saturated aqueous NaHC03, brine, dried (MgS04) , and concentrated. Flash chromatography (1% MeOH:CHCl3) provided the title compound as a white solid, mp 161.5-163.5°C; FAB-MS 748 (m+1) .
EXAMPLE 14
N- fN- fl-Methyl-N- f (phenylmethoxy) carbonyl! -D-histidyl! -
0- (phenylmethyl) -L-tyrosyll -0- (phenylmethyl) -L-serine. methyl ester (Cbz-D-His (1-Me) -Tyr(OBn) -Ser(OBn) -C02Me) According to Example 13, by substituting 1-methyl- D-histidine for 1-methyl-L-histidine, the title compound was obtained; FAB-MS 748 (m+1) . EXAMPLE 15 N- fL-2-Amino-N- fN- f (Phenylmethoxy) carbonyl! -D- histidyl! -4- f4- (phenylmethoxy)phenyl!butanoyl! -0- (phenylmethyl-L-serine. methyl ester {Cbz-D-His- homoTyr(OBn) -Ser(OBn) -CQ2Me}
According to Example 6, by substituting Boc- homoTyr(OBn) for Boc-Tyr(OBn) in Step 1, and substituting Cbz-D-His for Cbz-His in Step 3, the title compound was obtained; ES-MS 748 (m+1) .
EXAMPLE 16 N- f4-Phenyl-N- fN- f (phenylmethoxy) carbonyl! -L-histidyll - L-phenylalanyl! -O- (phenylmethyl) -L-serine. methyl ester {Cbz-His-Phe(4-Ph) -Ser(OBn) -CQ2Me} According to Example 6, by substituting Boc-
Phe(4-Ph) for Boc-Tyr(OBn) in Step 1, the title compound was obtained, mp 184-187°C; FAB-MS 704 (m+1) .
EXAMPLE 17 N- fO- (Phenylmethyl) -NfN- f f (Phenylmethyl)amino! - carbonyl! -L-histidyll -L-tyrosyll -0- (phenylmethyl) - serine. methyl ester {BnNHCO-His-Tyr(OBn) -Ser(OBn) -
CQ2Me}
Step 1: Fmoc-His (Tr) -Tyr(OBn) -Ser(OBn) -C02Me According to Example 13, Step 2, by substituting
Fmoc-His (Tr) for Cbz-His (1-Me) , the title compound was obtained, mp 82-92°C.
Step 2: His (Tr) -Tyr(OBn) -Ser(OBn) -C02Me Piperidine (4.0 mL) was added to a slurry of
Fmoc-His (Tr) -Tyr(OBn) -Ser(OBn) -C02Me (from Step 1 above, 1.85 g, 1.74 mmol) in CH2C12 (20 mL) . The solution was stirred for 2 hours at room temperature, then concentrated. The residue was taken up in EtOAc (150 mL) , washed with water (3 x 50 mL) , dried (MgS04) , and concentrated. The resulting oil was triturated with Et20/hexane. Flash chromatography of the residue (2% MeOH/CHCl3) gave 1.03 g of the title compound as a foam, mp 61.5-70°C; ES-MS 843 (m+1).
Step 3: BnNHCO-His (Tr) -Tyr(OBn) -Ser(OBn) -CQ2Me
Benzyl isocyanate (0.053 mL, 0.43 mmol) was added in one portion to a solution of His(Tr) -Tyr(OBn) - Ser(OBn) -C02Me (from Step 2 above, 0.33 g, 0.39 mmol) in EtOAc (5 mL) . The resulting slurry was stirred for 3 hours at room temperature, then concentrated to yield the title compound (0.4 g) , which was used without further purification.
Step 4: BnNHCO-His-Tyr(OBn) -Ser(OBn) -CO-.Me According to Example 8, by substituting BnNHCO-
His(Tr) -Tyr(OBn) -Ser(OBn) -C02Me for Cbz-His(Tr) - Tyr(OBn) -Ser(OBn) -C02Me, the title compound was obtained, mp 196.5-199°C; ES-MS 733 (m+1).
EXAMPLE 18
N- fN- fN- (l-Oxo-3-phenylpropyl) -L-histidyll -O- (phenylmethyl) -L-tyrosyl! -O- (phenylmethyl) -L-serine. methyl ester (PhCH2CH2CO-His-Tyr(OBn) -Ser(OBn) -CQ2Me} Step 1: PhCH CH2CO-His (Tr) -Tyr(OBn) -Ser(OBn) -CQMe To a cooled (0°C) solution of His(Tr) -Tyr(OBn) -
Ser(OBn) -C02Me (from Example 17, Step 2 above, 0.33 g, 0.39 mmol) in THF (5 mL) was added Et3N (0.06 mL, 0.43 mmol) followed by phenylpropionyl chloride (0.064 mL, 0.43 mmol). The resulting slurry was brought to room temperature and stirred overnight. The mixture was partitioned between EtOAc and saturated aqueous NaHC03. The organic layer was washed with brine, dried (MgS04) , and concentrated to yield the title compound as a solid which was used without further purification. Step 2: PhCH2CH CO-His-Tyr(OBn) -Ser(OBn) -CC Me
According to Example 8, Step 3, by substituting PhCH2CH2CO-His(Tr) -Tyr(OBn) -Ser(OBn) -C02Me for Cbz-D- His (Tr) -Tyr(OBn) -Ser(OBn) -C02Me, the title compound was obtained, mp 193-196.5°C; ES-MS 732 (m+1) .
EXAMPLE 19 NQ.- fN- f (Phenylmethoxy) carbonyl! -L-histidyl! - 0- (phenylmethyl) -N- f2- (phenylmethoxy)ethyl! - L-tyrosinamide {Cbz-His-Tyr(OBn) -C0NHCH2CH20Bn} Step 1: Cbz-His-Tyr(OBn) -C02Me
According to Example 6, Step 3, by substituting Tyr(OBn) -C02Me-TFA for Tyr(OBn) -Ser(OBn) -C02Me-TFA, the title compound was obtained as a white powder, mp 145-148°C; CI-MS 557 (m+1) .
Step 2: Cbz-His-Tyr(OBn)
According to Example 7, by substituting Cbz-His- Tyr(OBn) -C02Me for Cbz-His-Tyr(OBn) -Ser(OBn) -C02Me, the title compound was obtained as a white powder, mp 79-92°C; CI-MS 543 (m+1) .
Step 3: Cbz-His -Tyr(OBn) -CONHCH2CH2OBn
To a solution of Cbz-His-Tyr(OBn) (from Step 2 above, 0.43 g, 0.79 mmol) in DMF (4 mL) at 0°C was added HOBT (0.15 g, 0.95 mmol) and DCC (0.20 g, 0.95 mmol) . A solution of 2- (phenylmethoxy)ethylamine (0.12 g, 0.79 mmol) in DMF (l mL) was then added. The mixture was allowed to warm to room temperature and stirred overnight. The mixture was filtered, diluted with CHC13, washed twice with saturated aqueous NaHC03, washed with brine, dried over MgS04, and concentrated. Flash chromatography (3-5% MeOH/CHCl3) afforded 0.34 g (63%) of the title compound as a white solid, mp 136-150°C; FAB-MS 676 (m+1); Anal. Calc. for C39H41N506:
C, 69.32; H, 6.12; N, 10.36; Found: C, 69.43; H, 6.24; N, 10.45.
EXAMPLE 20
Nα- fN- f (Phenylmethoxy) carbonyl! -D-histidyll -N- f2- (phenylmethoxy)ethyl! -0- (phenylmethyl) -L- tyrosinamide {Cbz-D-His-Tyr(OBn) -CONHCH2CH2OBn}
According to Example 6, by substituting 2- (phenyl- methoxy)ethyla ine for Ser(OBn) -TFA and omitting Et3N in Step 1 and by substituting Cbz-D-His for Cbz-His in Step 3, the title compound was prepared, mp 161-165°C; FAB-MS 676 (m+1) .
EXAMPLE 21
NQ.- fN-Methyl-Nf (phenylmethoxy) carbonyl! -D-histidyll -N- f2- (phenylmethoxy)ethyl1 -0- (phenylmethyl) -L- tyrosinamide {Cbz-D-His- (N-Me)Tyr(OBn) -CONHCH2CH2OBn} According to Example 20, by substituting Boc- (N-Me)Ty (OBn) for Boc-Tyr(OBn) , the title compound was obtained, mp 64-78°C; ES-MS 690 (m+1) .
EXAMPLE 22 NQ.- fo.-Methyl-N- fN- f (phenylmethoxy) carbonyl! - D-histidyll -N- f2- (phenylmethoxy) ethyl! -O- (phenyl¬ methyl) -L-tyrosinamide {Cbz-D-His- (o?-Me)Tyr(OBn) - CONHCH2CH2OBn.
According to Example 20, by substituting Boc- (θ!-Me)Tyr(OBn) for Boc-Tyr(OBn) , the title compound was obtained, mp 66-78°C; ES-MS 690 (m+1) . EXAMPLE 23 N- (2-Phenylethyl) -Na- fN- f (phenylmethoxy) carbonyl! - L-histidyl! -0- (phenylmethyl) -L-tyrosinamide {Cbz-His-Tyr(OBn) -C0NHCH CH2Ph) According to Example 19, Step 3, by substituting
2-phenylethylamine for 2- (phenylmethoxy) ethylamine, the title compound was obtained as a white solid, mp 188-189.5°C; FAB-MS 646 (m+1) .
EXAMPLE 24
N- fN- fN- f (Phenylmethoxy) carbonyll -L-histidyl! -
0- (phenylmethyl) -L-tyrosyll -3- (3-pyridinyl) -L-alanine. methyl ester {Cbz-His-Tyr(OBn) -Pyr-CQ2Me}
According to Example 19, Step 3, by substituting Pyr-C02Me for 2- (phenylmethoxy) ethylamine, the title compound was obtained as a white solid, mp 180-182.5°C (dec) ; FAB-MS 705 (m+1) .
EXAMPLE 25 (S.R) -N- f2- (4-Benzyloxy-phenyl) -1- (3-phenoxy- propylcarbamoyl) -ethyl! -2- f3- (4-ethoxy-phenyl) - ureidol -3- (3H-imidazol-4-yl) -propionamide ( (4-Et0Ph)NHC0-D-His-Tyr(0Bn) -CONH(CH ) 3OPh) Step 1. Boc-Tyr(OBn) -CONH(CH ) 3OPh 2- (Phenylmethoxy) ethylamine (0.81 g, 5.4 mmol) was added to a premixed solution of EDAC (1.2 g, 6.5 mmol), HOBT (0.87 g, 6.5 mmol), and Boc-Tyr(OBn) -OH (2.0 g, 5.4 mmol) in dry DMF (15 mL) . The resulting mixture was stirred for 18 hours at room temperature. The solution was diluted with 1:1 EtOAc:Et20 (40 mL) , washed with saturated aqueous NaCl (4 x 10 mL) , dried (MgS04) , filtered, and concentrated in vacuo to provide a solid which was further purified by trituration with hexane to give the pure product, mp 145-146"C. Step 2. Tyr(OBn) -CONH(CH2)3OPh
Dry HC1 gas was bubbled into an ice cold solution of Boc-Tyr(OBn) -CONH(CH2)3OPh (from Step 1 above, 2.0 g, 3.9 mmol) in MeOH (15 mL) for 4 minutes. The resulting mixture was stirred for 1 hour at 0*C and then allowed to warm to room temperature and stir 1 hour. The solution was concentrated in vacuo to provide a solid which was triturated with ether to provide Tyr(OBn) -CONH(CH2)3OPh-HCl; CI-MS 405 (m+1). The title compound was suspended in CHC13, cooled in an ice bath, and NH3 gas was bubbled through the mixture for 2 minutes. The NH4C1 was filtered off, and the supernate was concentrated in vacuo to yield the free base of the title compound which was used in the next step without further purification.
Step 3. Fmoc-D-His (Tr) -Tyr(OBn) -CONH(CH2)-.OPh
To a solution of HOBT (0.48 g, 3.5 mmol) in DMF (10 mL) was added Fmoc-D-His(Tr) -C02H (2.0 g, 3.2 mmol) followed by EDAC (0.67 g, 3.5 mmol). The mixture was stirred at room temperature for 20 minutes before adding a solution of Tyr(OBn) -CONH(CH2)3OPh (from Step 2 above, 1.4 g, 3.2 mmol) in DMF (10 mL) . The mixture was stirred overnight at room temperature before partitioning between a mixture of water (20 mL) and 1:1 Et20:EtOAc (50 mL) . The layers were separated, and the organic phase was washed with saturated aqueous NaCl (4x 20 mL) and dried (MgS04) . Filtration and concentration in vacuo provided an oil which was further purified by flash chromatography (Si02, CHC13: MeOH eluent) to give the protected His-Tyr dipeptide; FAB-MS 1006 (m) .
Step 4. D-His(Tr) -Tyr(OBn) -CONH(CH2)3OPh Fmoc-D-His(Tr) -Tyr(OBn) -CONH(CH2)3OPh (from Step 3 above, 1.0 g, 0.99 mmol) in CH2C12 (5 mL) was treated with piperidine (0.18 g, 2.1 mmol) . The resulting mixture was stirred 2 hours before concentrating in vacuo and purifying the resulting oil by flash chromatography (Si02, CHCl3:MeOH eluent) to give (4-Et0Ph)NHC0-D-His (Tr) -Tyr(OBn) -CONH(CH2)30Ph; ES-MS 784 (m+1) .
Step 5. (4-Et0Ph)NHC0-D-His(Tr) -Tyr(OBn) -CONH(CH )3OPh D-His(Tr) -Tyr(OBn) -CONH(CH2)3OPh (from Step 4 above, 0.55 g, 0.7 mmol) in CH2C12 (5 mL) was treated with 4-ethoxyphenyl isocyanate (0.1 g, 0.7 mmol) . The resulting mixture was stirred 1 hour at room temperature. Concentrated in vacuo. The resulting oil was purified by flash chromatography (Si02, CHCl3:MeOH eluent) to give (4-EtOPh)NHCO-D-His (Tr) -Tyr(OBn) - CONH(CH2)3OPh; ES-MS 947 (m+1) .
Step 6. (4-EtOPh)NHCO-D-His-Tyr(OBn) -CONH(CH2) 3OPh (4-EtOPh)NHCO-D-His(Tr) -Tyr(OBn) -CONH(CH2) 3OPh (from Step 5 above, 0.5 g, 0.52 mmol) in MeOH (5 mL) was treated with Pyridine-HCl (catalytic) . The resulting mixture was stirred at 65°C for 6 hours. Concentrated in vacuo to obtain an oil which was purified by by flash chromatography (Si02, CHCl3:MeOH eluent) to give (4-Et0-Ph)NHC0-D-His-Tyr(OBn) - CONH(CH2)3OPh, mp 185-187°C; ES-MS 705 (m+1) .
EXAMPLE 26 (S.R) -N- {2- (4-Benzyloxy-phenyl) -1- f3- (2-methoxy- phenyl) -propylcarbamoy11 -ethyl)-3- (3H-imidazol-4-yl) - 2-phenylacetylamino-propionamide {PhCH2CO-D-His- Tyr(OBn)- CONH(CH ) 3 (2-MeOPh) ) Step 1. Boc-Tyr(OBn) -CONH(CH2)3 (2-MeOPh)
According to Example 25, Step 1, by substituting 3- (2-methoxyphenyl) propyl amine for 2- (phenylmethoxy) - ethylamine, the title compound was obtained as a white solid, mp 125-126.5°C.
Step 2. Tyr(OBn) -CONH(CH2)3 (2-MeOPh) According to Example 25, Step 2, by substituting
Boc-Tyr(OBn) -CONH(CH2) 3 (2-MeOPh) for Boc-Tyr(OBn) - CONH(CH2) 3OPh, the title compound was obtained as a white solid; CI-MS 419 (m+1) .
Step 3. Fmoc-D-His (Tr) -Tyr(OBn) -CONH(CH2)3 (2-MeOPh)
According to Example 25, Step 3, by substituting Tyr(OBn) -CONH(CH2) 3 (2-MeOPh) for Tyr(OBn) - CONH(CH2) 3OPh, the title compound was obtained as a foam; ES-MS 1020 (m) .
Step 4. D-His(Tr) -Tyr(OBn) -CONH(CH2) 2 (2-MeOPh)
According to Example 25, Step 4, by substituting Fmoc-D-His (Tr) -Tyr(OBn) -CONH(CH2) 3 (2-MeOPh) for Fmoc-D- His (Tr) -Tyr(OBn) -CONH(CH2) 3OPh, the title compound was obtained as a white foam; ES-MS 798 (m+1) .
Step 5. PhCH2CO-D-His (Tr) -Tyr(OBn) -CONH(CH2) 3 (2-MeOPh) To a solution of D-His (Tr) -Tyr(OBn) -
CONH(CH2)3(2-MeOPh) (0.4 g, 0.5 mmol) in CH2C12 (5 mL) was added N-methyl morpholine (0.05 g, 0.5 mmol) followed by phenyl acetyl chloride (0.08 g, 0.5 mmol).
The resulting mixture was stirred 2 hours at room temperature. Diluted with DCM and washed with saturated aqueous NaHC03, saturated aqueous NaCl, and dried (MgS04) . Purified by flash chromatography (Si02,
CHCl3:MeOH eluent) . The title compound was obtained as a foam; FAB-MS 916 (m) .
Step 6. PhCH2CO-D-His-Tyr(OBn) -CONH(CH2) , (2-MeOPh) According to Example 25, Step 6, by substituting
PhCH2CO-D-His(Tr) -Tyr(OBn) -CONH(CH2) 3 (2-MeOPh) for (4-EtOPh)NHCO-D-His(Tr) -Tyr(OBn) -CONH(CH2) 3OPh, the title compound was obtained as a white foam; ES-MS 674 (m+1) .
EXAMPLE 27
(S.R) -N- f2- (4-Benzyloxy-phenyl) -1-phenethylcarbamoyl- ethyl! -3- (3H-imidazol-4-yl) -2- f3- (4-phenoxy-phenyl) - ureidol -propionamide { (4-PhOPh)NHCO-D-His-Tyr(OBn) - CONH(CH2)2Ph} Step 1. Boc-Tyr(OBn)CONH(CH2) Ph
According to Example 25, Step 1, by substituting phenethylamine for 2- (phenylmethoxy) ethylamine, the title compound was obtained as a white solid; CI-MS 475 (m+1) .
Step 2. Tyr(OBn) -CONH(CH2) 2Ph
According to Example 25, Step 2, by substituting BocTyr(OBn) -CONH(CH2)2Ph for BocTyr(OBn) -CONH(CH2) 3OPh, the title compound was obtained as a white solid; CI-MS 375 (m+1) .
Step 3. Fmoc-D-His (Tr) -Tyr(OBn) -CONH(CH2) Ph
According to Example 25, Step 3, by substituting Tyr(OBn) -CONH(CH2)2Ph for Tyr(OBn) -CONH(CH2) 3OPh, the title compound was obtained as a foam; ES-MS 977 (m+1) .
Step 4. Fmoc-D-His-Tyr(OBn) -CONH(CH2) 2Ph
Fmoc-D-His (Tr) -Tyr(OBn) -CONH(CH2)2Ph (1.2 g, 1.6 mmol) in MeOH (5.mL) was treated with Pyridine-HCl (catalytic) . The resulting mixture was stirred at 65°C overnight and concentrated in vacuo to obtain an oil which was purified by by flash chromatography (Si02, CHCl3:MeOH eluent) to give a white solid; ES-MS 734 (m+1) . Step 5. (4-PhOPh)NHCO-D-His-Tyr(OBn) -CONH(CH2)2Ph
Fmoc-D-His-Tyr(OBn) -CONH(CH2)2Ph (0.6 g, 0.8 mmol) in CH2C12 (5 mL) was treated with piperdine (0.14 g, 1.6 mmol) . The resulting mixture was stirred 2 hours before concentrating in vacuo and purifying the resulting by flash chromatography (Si02, CHCl3:MeOH eluent) to give D-His-Tyr(OBn) -CONH(CH2)2Ph. The foam was dissolved in CH2C12 (5 mL) and treated with 4-phenoxyphenyl isocyanate (0.05 g, 0.23 mmol). The resulting mixture was stirred 1 hour at room temperature, concentrated in vacuo, and purified the resulting oil by flash chromatography (Si02, CHCl3:MeOH eluent) to obtain (4-PhOPh)NHCO-D-His-Tyr(OBn) - CONH(CH2)2Ph as a foam; ES-MS 723 (m+1).
EXAMPLE 28 (S.R) -N- fl- (4-Benzyloxy-benzyl) -2- (4-benzyl-piperazin- 1-yl) -2-oxo-ethyπ -3- (3H-imidazol-4-yl) -2- (toluene- 4-sulfonylamino) -propionamide { (4-MePh)S02-D-His- Tyr(OBn) -CO(4-Bn-piperazin-l-yl) -HCl}
Step 1. Boc-Tyr(OBn) -CO(4-Bn-piperazin-l-yl)
According to Example 25, Step 1, by substituting 1-benzylpiperizine for 2- (phenylmethoxy)ethylamine, the title compound was obtained as a white solid; CI-MS 530 (m+1) .
Step 2. Tyr(OBn) -CO(4-Bn-piperazin-l-yl)
According to Example 25, Step 2, by substituting Boc-Tyr(OBn) -CO(4-Bn-piperazin-l-yl) for Boc-Tyr(OBn) - CONH(CH2)3OPh, the title compound was obtained as a white solid; CI-MS 430 (m+1) . Step 3. Fmoc-D-His (Tr) -Tyr(OBn) -CO(4-Bn-piperazin- 1-yl) According to Example 25, Step 3, by substituting Tyr(OBn) -C0(4-Bn-piperazin-l-yl) for Tyr(OBn)- CONH(CH2) 3OPh, the title compound was obtained as a foam; ES-MS 1032 (m+1) .
Step 4. (4-MePh)SQ -D-His(Tr) -Tyr(OBn) -CO (4-Bn- piperazin-l-yl) Fmoc-D-His-Tyr(OBn) -CONH(CH2)3OPh, (0.7 g,
0.69 mmol) in CH2C12 (5 mL) was treated with piperidine (0.14 g, 1.6 mmol) . The resulting mixture was stirred 2 hours before concentrating in vacuo and purifying the resulting oil by flash chromatography (Si02, CHCl3:MeOH eluent) to give D-His-Tyr(OBn) -CONH(CH2)2Ph. The foam was dissolved in CH2C12 (5 mL) and treated with pyridine (0.05 g, 0.63 mmol) , followed by 4-toluenesulfonyl chloride (0.12 g, 0.63 mmol) . The resulting mixture was stirred 3 hours at room temperature, concentrated in vacuo, and purified the resulting oil by flash chromatography (Si02, CHCl3:MeOH eluent) to obtain (4-MePh)S02-D-His (Tr) -Tyr(OBn) - CO(4-Bn-piperazin-l-yl) ; ES-MS 963 (m) .
Step 5. (4-MePh)S02-D-His-Tyr(OBn) -CO (4-Bn-piperazin- l-yl) -HC1 (4-MePh)S02-D-His(Tr) -Tyr(OBn) -CO(4-Bn-piperazin- l-yl) (0.21 g, 0.22 mmol) was treated with 80% aqueous HC1 (3 mL) and heated to 80°C for 5 minutes. The mixture was cooled and diluted with water (5 mL) . The solid was filtered off, and the supernate was concentrated in vacuo to provide an oil. The oil was dissolved in water (15 mL) , frozen, and lyophilized to provide (4-MePh)S02-D-His-Tyr(OBn) -CO(4-Bn-piperazin- 1-yl) -HC1; ES-MS 720 (m) . EXAMPLE 29 Nα- fN- f (Phenylmethoxy) carbonyl! -L-histidyll -0- (phenylmethyl) -N-methyl-N- f2- (phenylmethoxy)ethyl! - L-tyrosinamide {Cbz-His-Tyr(OBn) -CON(Me)CH2CH2OBn} According to Example 19, Step 3, by substituting
N-methyl-N- [2- (phenylmethoxy) ethyl] amine for 2- (phenylmethoxy) ethylamine, the title compound was prepared; FAB-MS 690 (m+1) .
The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Claims

1. A compound of the Formula I:
wherein: n 1 or 2; A COR3, C02RJ 3, C r-0rsNκrHuRτ>J-, Cr-ScRr.3 C(S)0R3, C(S)NHR3, CF3S02, aryl-S02, or alkyl-S02, wherein R3 is alkyl, (CH2)m-cycloalkyl, (CH2)m-aryl, (CH2)m-heteroaryl, or (CH2)mO-alkyl, and m = 0, 1, 2, or 3;
R independently H or Me; Y independently H or Me; Z independently H or Me;
R1 H, CO-aryl, (CH2)m-aryl, 0 (CH2)m-cycloalkyl, 0(CH2)m-aryl, or 0(CH2)m-heteroaryl wherein is as defined above and R1 is located at either the meta or para position;
X one to four substituents, including H, alkyl, CF3, F, Cl, Br, I, HO, MeO, N02, NH2, N(Me)2, OP03H2, or CH2P03H2; and
NR(CH2)nC02R3, NR(CH2)nCONHR3, NR(CH2)nR3, NR(CH2)n+1OR4, NR(CH2)n+1SR4, NRCH(C0R5) (CH2)n-heteroaryl,
NRCH(C0R5) (CH2)nOR3, NRCH(COR5) (CH2)nSR3,
or N —R wherein R, R , and n are
\ / as defined above, R4 = H or R3, and R5 = OH, NH2, OR3, or NHR3; an optical isomer, diastereomer, or a pharmaceutically acceptable salt thereof.
A compound according to Claim 1 which is a compound of Formula II:
wherein:
A' = C02R3, CONHR3, C(S)NHR3, or aryl-S02, wherein
R3 is alkyl, (CH2)m-cycloalkyl, (CH2)m-aryl, (CH2)m-heteroaryl, and m = 0, 1,
2 or 3;
R = independently H or Me;
Y = independently H or Me;
Z = independently H or Me;
R1' = (CH2)m-aryl, 0(CH2)m-aryl, OP03H2, or
CH2P03H2, wherein m is as defined above;
R2' = NR(CH2)20R4, NR(CH2)2SR4, NRCH(COR5)CH2OR3, or NRCH(COR5)CH2SR3, wherein R3 and n are as defined above, R4 = H or R3, and R5 = OH,
NH 2' OR3, or NHR3; an optical isomer, diastereomer, or a pharmaceutically acceptable salt thereof.
3. A compound according to Claim 1 wherein A is C02R3 or CONHR3.
4. A compound according to Claim 1 wherein at least one of Y and Z is Me.
5. A compound according to Claim 1 wherein R2 is NH(CH2)2OR4 or NHCH(COR5)CH2OR3.
6. A compound according to Claim 1 wherein A is NHCONHR3, R2 is (CH2)2OR4, and at least one of Y and Z is Me.
7. A compound according to Claim 1 selected from the group consisting of:
Cbz-His-Tyr(OBn) -Ser(OBn) -C02Me; Cbz-His-Tyr(OBn) -Ser(OBn) -CONH2; Cbz-His-Tyr(OBn) -Ser(OBn) -CONHEt; and Cbz-His-Tyr(OBn) -Ser(OBn) .
8. A compound according to Claim 1 selected from the group consisting of:
Cbz-His-Tyr(OBn) -D-Ser(OBn) -C02Me; Cbz-D-His-Tyr(OBn) -Ser(OBn) -CONH2; Cbz-D-His-Tyr(OBn) -Ser(OBn) -CONHEt; Cbz-D-His-Tyr(OBn) -Ser(OBn) -C02Me; and Cbz-D-His-Tyr(OBn) -Ser(OBn) .
9. A compound according to claim 1 selected from the group consisting of:
Cbz-His (1-Me) -Tyr(OBn) -Ser(OBn) -C02Me; Cbz-His (1-Me) -Tyr(OBn) -Ser(OBn) -CONH2; Cbz-His (1-Me) -Tyr(OBn) -Ser(OBn) -CONHEt; Cbz-His (1-Me) -Tyr(OBn) -Ser(OBn) ; Cbz-D-His (1-Me) -Tyr(OBn) -Ser(OBn) -C02Me; Cbz-D-His (1-Me) -Tyr(OBn) -Ser(OBn) -CONH2; Cbz -D- His ( 1 -Me) - Tyr (OBn) - Ser (OBn) - CONHEt ; and Cbz -D- His ( 1 -Me) - Tyr (OBn) - Ser (OBn) .
10. A compound according to claim 1 selected from the group consisting of:
Cbz-His- (C--Me)Tyr(OBn) -Ser(OBn) -C02Me; Cbz-His- (o;-Me)Tyr(OBn) -Ser(OBn) -CONH2; Cbz-His- (C--Me)Tyr(OBn) -Ser(OBn) -CONHEt;
Cbz-His- (c--Me)Tyr(OBn) -Ser(OBn) ; Cbz-His-D- (θ--Me)Tyr(OBn) -Ser(OBn) -C02Me; Cbz-His-D- (θ--Me)Tyr(OBn) -Ser(OBn) -CONH2; Cbz-His-D- (Qj-Me)Tyr(OBn) -Ser(OBn) -CONHEt; and Cbz-His-D- (α-Me)Tyr(OBn) -Ser(OBn) .
11. A compound according to Claim 1 selected from the group consisting of:
Cbz-D-His-homoTyr(OBn) -Ser(OBn) -C02Me; Cbz-His-Phe(4-Ph) -Ser(OBn) -C02Me; Cbz-D-His-Phe(4-Ph) -Ser(OBn) -C02Me;
Cbz-His-Tyr(OBn) -Pyr-C02Me; and Cbz-D-His-Tyr(OBn) -Pyr-C02Me.
12. A compound according to Claim 1 selected from the group consisting of:
Cbz-His-Tyr(OBn) -CONHCH2CH2OBn; Cbz-D-His-Tyr(OBn) -CONHCH2CH2OBn; Cbz-His- (N-Me)Tyr(OBn) -CONHCH2CH2OBn;
Cbz-D-His- (N-Me)Tyr(OBn) -CONHCH2CH2OBn; Cbz-His-Tyr(OBn) -CONH(CH2)2Ph; and Cbz-D-His-Tyr(OBn) -CONH(CH2)2Ph.
13. A compound according to Claim 1 selected from the group consisting of:
Cbz-His-Tyr(OBn) -Gly-C02Bn; Cbz-D-His-Tyr(OBn) -Gly-C02Bn; Cbz-His-Tyr(OBn) -Gly-CONHBn; and Cbz-D-His-Tyr(OBn) -Gly-CONHBn.
14. A compound according to Claim 1 selected from the group consisting of:
BnNHCO-His-Tyr(OBn) -Ser(OBn) -C02Me; BnNHCO-His-Tyr(OBn) -Ser(OBn) -CONH2; BnNHCO-His-Tyr(OBn) -Ser(OBn) -CONHEt; BnNHCO-His-Tyr(OBn) -Ser(OBn) ; BnNHCO-His-Tyr(OBn) -C0NHCH2CH2OBn; and BnNHCO-His-Tyr(OBn) -CONHCH2CH2CH2OPh.
15. A compound according to Claim 1 selected from the group consisting of:
BnNHCO-D-His-Tyr(OBn) -Ser(OBn) -C02Me; BnNHCO-D-His-Tyr(OBn) -Ser(OBn) -CONH2; BnNHCO-D-His-Tyr(OBn) -Ser(OBn) -CONHEt; BnNHCO-D-His-Tyr(OBn) -Ser(OBn) ; BnNHCO-D-His-Tyr(OBn)-CONHCH2CH2OBn; and BnNHCO-D-His-Tyr(OBn) -CONHCH2CH2CH2OPh.
16. A compound according to Claim l selected from the group consisting of:
Cbz-His-Tyr(OBn) -CON(Me)CH2CH2OBn; (4-EtOPh)NHCO-D-His-Tyr(OBn) -CONH(CH2) 3OPh; PhCH2CO-D-His-Tyr(OBn) -CONH(CH2)3- (2-MeOPh) ; (4-PhOPh)NHCO-D-His-Tyr(OBn) -COHN(CH2)2Ph; and
(4-MePh)S02-D-His-Tyr(OBn) -CO(4-Bn- piperazin-l-yl) .
17. A method of treating tissue proliferative diseases comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to Claim 1 in unit dosage form.
18. A pharmaceutical composition adapted for administration as an antiproliferative agent comprising a therapeutically effective amount of a compound according to Claim 1 in admixture with a pharmaceutically acceptable excipient, diluent or carrier.
19. A method of treating cancer comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to Claim 1 in unit dosage form.
20. A pharmaceutical composition adapted for administration as an anticancer agent comprising a therapeutically effective amount of a compound according to Claim 1 in admixture with a pharmaceutically acceptable excipient, diluent or carrier.
21. A method of treating restenosis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to Claim 1 in unit dosage form.
22. A pharmaceutical composition adapted for administration as a restenosis inhibiting agent comprising a therapeutically effective amount of a compound according to Claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
23. A process for the preparation of organic compounds according to Claim l, or a pharmaceutically acceptable salt thereof, comprising the steps of employing solid phase support technology and sequentially coupling building blocks utilizing a - 62 - solid phase peptide synthesizer, cleaving the organic compound from the solid phase support and subsequently optionally modifying the C-terminus of the organic compound in solution phase to afford a compound or a pharmaceutically acceptable salt thereof of Formula I.
24. A process for the preparation of compounds according to Claim 1, or a pharmaceutically acceptable salt thereof, comprising the steps of employing solution phase technology and sequentially coupling building blocks to afford a compound or a pharmaceutically acceptable salt thereof of Formula I.
25. A process for the preparation of compounds according to Claim 1, or a pharmaceutically acceptable salt thereof, comprising simultaneous synthesis of compounds of Formula I in a multiple simultaneous synthesis apparatus, using a D- or L- histidine containing dipeptide derivative that is supported on 2-chlorotrityl resin with sequential deprotection and acylation of the N-terminus followed by sequential deprotection of the carboxy terminus, carboxyl activation and condensation with a series of amines, followed by cleavage from the solid support.
EP94930725A 1993-11-05 1994-10-12 Substituted di- and tripeptide inhibitors of protein:farnesyl transferase Withdrawn EP0730605A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14873593A 1993-11-05 1993-11-05
US148735 1993-11-05
US30330194A 1994-09-13 1994-09-13
PCT/US1994/011553 WO1995012612A1 (en) 1993-11-05 1994-10-12 Substituted di- and tripeptide inhibitors of protein:farnesyl transferase
US303301 1999-04-30

Publications (1)

Publication Number Publication Date
EP0730605A1 true EP0730605A1 (en) 1996-09-11

Family

ID=26846110

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94930725A Withdrawn EP0730605A1 (en) 1993-11-05 1994-10-12 Substituted di- and tripeptide inhibitors of protein:farnesyl transferase

Country Status (10)

Country Link
EP (1) EP0730605A1 (en)
JP (1) JP3597863B2 (en)
KR (1) KR100362338B1 (en)
AU (1) AU681454B2 (en)
CA (1) CA2170766A1 (en)
FI (1) FI961819A0 (en)
HU (1) HUT75308A (en)
NO (1) NO961814L (en)
NZ (1) NZ275691A (en)
WO (1) WO1995012612A1 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113196A0 (en) * 1994-03-31 1995-06-29 Bristol Myers Squibb Co Imidazole derivatives and pharmaceutical compositions containing the same
US5523456A (en) * 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JPH10508005A (en) * 1994-09-29 1998-08-04 メルク エンド カンパニー インコーポレーテッド Thiol-free farnesyl-protein transferase inhibitors
US5652257A (en) * 1994-09-29 1997-07-29 Merck & Co., Inc. Heterocycle-containing inhibitors of farnesyl-protein transferase
US5585359A (en) * 1994-09-29 1996-12-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5756528A (en) * 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5972984A (en) * 1995-06-06 1999-10-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
FR2736641B1 (en) * 1995-07-10 1997-08-22 Rhone Poulenc Rorer Sa NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5968965A (en) * 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5981562A (en) * 1996-01-30 1999-11-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
JP2000511527A (en) * 1996-05-22 2000-09-05 ワーナー―ランバート・コンパニー Inhibition of protein farnesyltransferase
US6300501B1 (en) 1996-05-22 2001-10-09 Warner-Lambert Company Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
ES2216189T3 (en) 1996-12-17 2004-10-16 Warner-Lambert Company Llc CYCLALKYL INHIBITORS PROTEIN FARNESILTRANSFERASA
US6013662A (en) 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
FR2757855B1 (en) * 1996-12-30 1999-01-29 Rhone Poulenc Rorer Sa NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6124465A (en) * 1997-11-25 2000-09-26 Rhone-Poulenc S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
US6423689B1 (en) 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
WO1999043658A1 (en) 1998-02-27 1999-09-02 Warner-Lambert Company Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
CA2317572A1 (en) 1998-04-02 1999-10-14 Jared Miller Wagner Pharmaceutical compositions and methods for use
DK1076663T3 (en) * 1998-04-27 2004-06-01 Warner Lambert Co Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors
KR20010080709A (en) 1998-12-10 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 Procollagen c-proteinase inhibitors
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
FR2796641B1 (en) 1999-07-22 2001-09-21 Aventis Pharma Sa NOVEL PROCESS FOR THE PREPARATION OF BENZOPERHYDROISOINDOLE COMPOUNDS
WO2005044780A1 (en) * 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative, addition salt thereof, and s1p receptor control agent
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
HUE035654T2 (en) 2006-04-19 2018-05-28 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
RS51780B (en) 2007-01-10 2011-12-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
MX2009009304A (en) 2007-03-01 2009-11-18 Novartis Ag Pim kinase inhibitors and methods of their use.
JP5378362B2 (en) 2007-05-21 2013-12-25 ノバルティス アーゲー CSF-1R inhibitors, compositions and methods of use
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2440058A4 (en) 2009-06-12 2012-11-21 Dana Farber Cancer Inst Inc Fused heterocyclic compounds and their uses
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2011115725A2 (en) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP2601293B1 (en) 2010-08-02 2017-12-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
CA2831730A1 (en) 2011-04-21 2012-10-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013062947A1 (en) 2011-10-26 2013-05-02 Allergan, Inc. Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
JP6106685B2 (en) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitors of C-JUN-N-terminal kinase (JNK)
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP6280554B2 (en) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Novel compounds that are ERK inhibitors
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
PT2925888T (en) 2012-11-28 2017-12-13 Merck Sharp & Dohme Compositions and methods for treating cancer
JP6387013B2 (en) 2012-12-20 2018-09-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Substituted imidazopyridines as HDM2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
JP6491202B2 (en) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Polycyclic inhibitors of cyclin dependent kinase 7 (CDK 7)
ES2676734T3 (en) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Heteroatomic compounds useful for the treatment of proliferative diseases
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107427521B (en) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 Inhibitors of cyclin dependent kinases
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
MX2019012233A (en) 2017-04-13 2020-01-14 Aduro Biotech Holdings Europe Bv Anti-sirp alpha antibodies.
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20210277009A1 (en) 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072033A1 (en) * 1991-06-28 1992-12-29 Jackson B. Gibbs Non-substrate inhibitors of farnesyl protein transferase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9512612A1 *

Also Published As

Publication number Publication date
FI961819A (en) 1996-04-29
WO1995012612A1 (en) 1995-05-11
KR100362338B1 (en) 2003-04-08
AU681454B2 (en) 1997-08-28
FI961819A0 (en) 1996-04-29
CA2170766A1 (en) 1995-05-11
NO961814L (en) 1996-05-06
NO961814D0 (en) 1996-05-03
AU7976094A (en) 1995-05-23
NZ275691A (en) 1998-03-25
HUT75308A (en) 1997-05-28
JPH09504547A (en) 1997-05-06
JP3597863B2 (en) 2004-12-08
HU9601193D0 (en) 1996-07-29

Similar Documents

Publication Publication Date Title
AU681454B2 (en) Substituted DI- and tripeptide inhibitors of protein:farnesyl transferase
AU682906B2 (en) Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
AU699629B2 (en) Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
AU3971295A (en) Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
CA2008116C (en) Glycine derivatives
US5470833A (en) Endothelin antagonistic peptide derivatives
EP1006122B1 (en) Phenethylamine derivatives
US5830868A (en) Substituted DI- and tripeptide inhibitors of protein: farnesyl transferase
US5763577A (en) Substituted tetra- and pentapeptide inhibitors of protein: farnesyl transferase
AU721786C (en) Cycloalkyl inhibitors of protein farnesyltransferase
MXPA97003208A (en) Tetra-y pentapeptidos substituidos deproteina inhibitors, farnesil transfer
KR840000054B1 (en) Process for the preparation of thymosin
CZ9902807A3 (en) Process for preparing organic compounds, particularly carba analogs of peptides
HRP930498A2 (en) Glycine derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960422

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 960422;SI PAYMENT 960422

RAX Requested extension states of the european patent have changed

Free format text: LT PAYMENT 960422;SI PAYMENT 960422

17Q First examination report despatched

Effective date: 19980325

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19991221